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Abstract 
Design and elaboration of novel drug eluting stents to produce tailored 
releases aiming for the reduction of restenosis after implantation 
Coronary artery disease is the most typical type of heart disease, killing more than 385,000 
people annually. Up to date, many different approaches have been tested in order to treat patients 
while trying to keep inflammatory responses to a minimum. Among these, the use of nanocarriers, 
multilayered coatings and gene therapy stand out as some of the most promising novel therapeutic 
strategies tested lately. Stents have been used throughout the years with different designs and 
coatings, achieving enhanced healing results with every new generation. Although their use is justified 
their results are not optimal, creating a need to develop better strategies to treat coronary artery 
diseases. 
We understand that a total liberation control of the pharmacological drug load from a medical 
device can profoundly change a patient’s outcome, therefore, becoming a priority of our work. Here, 
we present a way of producing in-lab and industrial scaled coatings for medical devices which are 
used to produce tailored multilayered coatings for drug eluting stents. Apart from this, an approach 
to treat coronary artery disease through gene therapy with nanocarriers is also introduced, opening 
new possibilities for localized treatments with drug eluting stents. Starting with the elaboration of 
methodologies and instrumentation required to produce tailored coatings, novel stent designs are 
created and studied in this work. This enables the production of new coatings and delivery systems 
which are tested in-vitro and in-vivo in order to prove their effectiveness. 
In conclusion, this thesis demonstrated that a tailored drug release can be achieved through 
multilayered designs and nanoparticle liberations, which can be applied to drug eluting stents to 
obtain a reduction in restenosis rates with promising results. 
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Resumen 
Design and elaboration of novel drug eluting stents to produce tailored 
releases aiming for the reduction of restenosis after implantation 
 Las enfermedades de arteria coronaria son el tipo más común de enfermedad cardíaca, 
matando a más de 385,000 personas anualmente. Hasta la fecha, se han probado muchos enfoques 
distintos a la hora de plantear tratamientos que mantengan las respuestas inflamatorias al mínimo. 
Entre estos, el uso de nanoparticulas, recubrimientos multicapa y terapia génica destacan como 
algunas de las estrategias terapéuticas novedosas más prometedoras. El uso de stents cardíacos 
se ha mantenido a lo largo de los años con diferentes diseños y recubrimientos, logrando mejores 
resultados con cada nueva generación. Aunque su uso está justificado, sus resultados no son 
óptimos, creando la necesidad de desarrollar mejores estrategias para tratar este tipo de 
enfermedades. 
Entendemos que un control total de la liberación de la carga farmacológica de un dispositivo 
médico puede cambiar profundamente los resultados de un paciente, convirtiéndose así en una 
prioridad de nuestro trabajo. Presentamos una forma de producir recubrimientos, a escala industrial 
y de laboratorio, orientados para dispositivos médicos y que se utilizan para producir recubrimientos 
multicapa a medida para stents con liberación de fármaco. Además de esto, también se presenta un 
enfoque para tratar enfermedades de arteria coronaria a través de la terapia génica con 
nanoportadores, lo que abre nuevas posibilidades para tratamientos localizados empleando stents 
con liberación de fármaco. Comenzando con la elaboración de metodologías e instrumentos 
necesarios para producir recubrimientos a medida, se crean y estudian nuevos diseños de stent a lo 
largo de este trabajo. Esto permite la producción de nuevos recubrimientos y sistemas de liberación 
los cuales son probados in-vitro e in-vivo para demostrar su efectividad. 
En conclusión, esta tesis demuestra que se puede lograr una liberación de fármacos a medida 
mediante diseños multicapa y liberación con nanoportadores, aplicable a stents con liberación de 
fármaco para obtener una reducción en las tasas de reestenosis con resultados prometedores. 
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Design and elaboration of novel drug eluting stents to produce tailored 
releases aiming for the reduction of restenosis after implantation 
 
 Les malalties d'artèria coronària són el tipus més comú de malaltia cardíaca, matant a més 
de 385,000 persones anualment. Fins a la data, s'han provat moltes estratègies diferents a l'hora de 
plantejar tractaments que mantinguin les respostes inflamatòries al mínim. Entre aquests, l'ús de 
nanopartícules, recobriments multicapa i teràpia gènica destaquen com algunes de les estratègies 
terapèutiques noves més prometedores. L'ús de stents cardíacs s'ha mantingut al llarg dels anys 
amb diferents dissenys i recobriments, aconseguint millors resultats amb cada nova generació. 
Encara que el seu ús està justificat, els seus resultats no són òptims, creant la necessitat de 
desenvolupar millors estratègies per tractar aquest tipus de malalties. 
Entenem que un control total de l'alliberament de la càrrega farmacològica d'un dispositiu mèdic 
pot canviar profundament els resultats d'un pacient, convertint-se així en una prioritat del nostre 
treball. Presentem una forma de produir recobriments, a escala industrial i de laboratori, orientats per 
a dispositius mèdics i que s'utilitzen per produir recobriments multicapa a mida per stents amb 
alliberament de fàrmac. A més d'això, també es presenta un enfocament per tractar malalties d'artèria 
coronària a través de la teràpia gènica amb nanoportadors, el que obre noves possibilitats per a 
tractaments localitzats emprant stents amb alliberament de fàrmac. Començant amb l'elaboració de 
metodologies i instruments necessaris per a produir recobriments a mida, es creen i estudien nous 
dissenys de stent al llarg d'aquest treball. Això permet la producció de nous recobriments i sistemes 
d’alliberació els quals són provats in-vitro i in-vivo per demostrar la seva efectivitat. 
En conclusió, aquesta tesi demostra que es pot aconseguir un alliberament de fàrmacs a mida 
mitjançant dissenys multicapa i alliberament amb nanoportadors, aplicable a stents amb alliberament 
de fàrmac per obtenir una reducció en les taxes de reestenosi amb resultats prometedors. 
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1. Introduction
Coronary artery disease (CAD) 
As a way to start this thesis, a background is presented which aims to provide the reader with 
some knowledge on drug eluting stents (DES) and medical terminology which go hand in hand with 
these medical devices. As the main issue being confronted in this work is CAD, this introduction will 
start off focusing on describing it and showing the most frequently used treatments. 
 CAD is the most typical type of heart disease, killing more than 385,000 people annually 
(Centers for Disease Control and Prevention (CDC) [1][2]). It is a serious and common ailment 
that can profoundly influence a patient’s prognosis and quality of life, caused by myocardial tissue 
ischemia. The mechanism through which coronary ischemia happens is the development of coronary 
atherosclerotic plaque. It starts with the deposition of fatty substances (cholesterol, fatty acids, etc.) 
in arteries, resulting in a narrowed blood vessel lumen and thus reduced myocardial oxygen supply. 
This type of ischemia can result in the following clinical syndromes: Coronary Artery Disease (CAD), 
angina pectoris and myocardial infarction (MI) [3]-[5]. Throughout this thesis, the focus will be drawn 
towards CAD and its treatment using tailored polymeric coated stents. 
 There are different therapeutic strategies to treat CAD, these include pharmacological 
treatments and myocardial reperfusion or revascularization. In addition to appropriate hygienic and 
dietary regimen (to reduce risk factors), administration of pharmacological agents is systematic and 
is done prior to any cardiovascular intervention, and may include [6][7] anti-thrombotic drugs, anti-
ischemic drugs and prophylactic or symptomatic lipid lowering drugs. 
Myocardial revascularization has been an established mainstay in the treatment of CAD for 
almost half a century. In the recent years, invasive cardiology has gained a pivotal role in the 
management of acute and stable heart disease by improving outcomes and/ or quality of life. The 
interventional strategies include: 
- Coronary Artery Bypass Graft (CABG): First performed in 1962, CABG is a surgical 
procedure which has been used in multivessel and left main stem disease for almost 40 
years. In CABG, bypass grafts are placed to the mid-coronary vessel beyond the culprit 
lesion(s), providing extra sources of nutrient blood flow to the myocardium and offering 
protection against the consequences of further proximal obstructive disease. The 
procedure is usually performed by stopping the heart, needing a cardiopulmonary 
bypass. Indications for CABG are: Chronic and unstable angina, acute MI, Failure of 
PTCA and severe CAD  [8][9]. 
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- Percutaneous Coronary Intervention (PCI): A non-surgical procedure that uses a 
catheter to place a stent to open up blood vessels in the heart that have been narrowed 
by plaque build-up. Although initially limited to Percutaneous Transluminal Coronary 
Angioplasty (PTCA), Percutaneous Coronary Intervention (PCI) now associates PTCA 
and several new techniques, such as stent implantation (bare-metal, BMS; and drug-
eluting, DES), atherectomy, distal protection during saphenous vein graft, 
thrombectomy, vascular brachytherapy, laser angioplasty and balloon angioplasty [10]. 
Coronary stent implantation is a procedure used for the permanent dilation of coronary 
artery stenosis in order to improve the myocardial perfusion and extensively for the 
coronary artery disease (CAD). 
As PCI is an interesting conceptual part of stent deployment, it feels necessary to present some more 
information about these techniques and how they were developed. 
The birth of interventionist cardiology and BMS 
In 1964, Charles Theodore Dotter and Melvin P. Judkins described the first angioplasty after 
using a balloon attached to the tip of a catheter for the treatment of the atherosclerotic vascular 
disease in the superficial femoral artery of the left leg [11][12]. In the mid-1970s, Andreas Gruentzing 
performed the first coronary balloon angioplasty, which marked the beginnings of interventionist 
cardiology and a major change in the treatment of patients with obstructive diseases of the coronary 
artery [12].  
Once access into the femoral, radial or brachial artery is gained, the tip of a long, flexible, soft 
plastic guiding catheter is seated within the opening of the coronary artery and x-ray movie pictures 
are recorded during the injection of radiopaque agents into the coronary artery. This is done so that 
the disease state and location can be readily assessed using real time x-ray visualization. After 
evaluating the x-ray movie pictures, the cardiologist estimates the size of the coronary artery and 
selects the type of balloon catheter and wire that will be used. The coronary guidewire, which is an 
extremely thin wire with a radio-opaque flexible tip, is inserted through the guiding catheter and into 
the coronary artery. After doing this, the tip of the wire is then passed across the stenosis. The 
guidewire now acts as a pathway for the balloon catheter leading it to the stenosis. The folded balloon 
is inserted into the site of the lesion, where it is inflated at an established pressure, reducing the 
obstructing plaques. Once the blood flow passage is open, it is deflated and removed (Figure 1). 
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Figure 1: Balloon angioplasty process [13]. At the left of this figure, a catheter is used to place a balloon on the area were 
the plaque has built up. A second image starting from the left shows how a balloon expands and compresses the plaque onto 
the artery wall. A third image starting from the left depicts a catheter extraction after plaque compression. At the right of 
the figure, two cross-sections are shown. One displays an artery cross-section before the treatment (top), while the other 
shows the resulting lumen after the procedure has been done (bottom).  
Since the beginning, a great number of medical advances have been made which have allowed 
percutaneous coronary interventions (PCI) to become an effective alternative treatment to coronary 
artery bypass surgery (CABG). Currently, PCI has become one of the most frequently performed 
invasive medical procedures in clinical practice [14]. 
In the end, PTCA procedures gave way to other PCI techniques such as bare metal stent 
implantation. Next, these two are described giving a general background of their development. PTCA 
causes plaque compression, but the major change in lumen geometry is caused by fracturing and 
fissuring of the atheroma, extending into the vessel wall at variable depths and lengths. This injury 
accounts for the three major limitations of PTCA - coronary artery dissection, abrupt vessel closure, 
and restenosis. Although balloon angioplasty progressed and was promptly adopted as a technique, 
rising from a success rate of 78% obtained in the first international register in 1977-1981 to a success 
rate of 90% in 1991-1994, it did not provide long-term solutions. It was often necessary to repeat the 
procedure due to problems of acute vascular occlusion (2-4%) and restenosis (30-50%), mainly in 
the first 6 months [12]. 
In 1969, Dotter began studies on the implantation of coil wires, the stent precursor, in animals 
[15]. As no satisfactory results were obtained, this device was abandoned until the early 1980s when 
it was taken up again by Dotter and Cragg through the use of nitinol wires [12][15]. Late in the same 
decade, Sigwart and Puel performed the first implantation in humans. It was a self-expandable stent 
known as a “Wall” stent [16]. At the same time, the Palmaz-Schatz balloon-expandable intracoronary 
stent was developed [12][17][18]. This first generation comprised three closed cell segments 
connected by two spiral-shaped segments commonly known as Palmaz-Schatz balloon expandable 
stents (Figure 2). Today, balloon-expandable stents are much more widely used than self-expandable 
stents( Figure 3) .
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Figure 2:  Palmaz-Schatz balloon-expandable stent [19]. This figure shows the metallic cell structure of the first balloon 
expandable stents. 
Figure 3: Implantation of a balloon-expandable stent [20]. At the left of this figure, a catheter is used to place a balloon on 
the area were the plaque has built up. A second image starting from the left shows how a balloon expands a stent which 
compresses the plaque onto the artery wall. A third image starting from the left depicts a catheter extraction after plaque 
compression while a stent remains on the affected area. At the right of the figure, two cross-sections are shown. One displays 
an artery cross-section before the treatment with a closed stent deployed on the affected area (top), while the other shows 
the resulting lumen after the procedure has been done (bottom). An expanded stent structure can be seen in this last image. 
Initially, the metal stent was used only in cases of restenosis of the native vessel or of the 
aortocoronary venous bypass graft and in acute occlusions caused during balloon angioplasty. The 
main danger of stents was the risk of subacute thrombotic occlusion of the coronary artery that could 
reach up to 18% of cases in the initial weeks of implantation. This led to the use of complex 
anticoagulation regimens with the attendant increase in bleeding events and prolonged hospital stays 
[16]. 
The publication of the results of the randomized studies on balloon vs. stent, BENESTENT I and 
II (Belgium Netherlands Stent) [12][21][22] and STRESS (Study on Stent Restenosis) [12][23] 
obtained results which indicated a lower restenosis rate and better long-term results with the stent. 
They also showed the advance in the study of anticoagulant-antiplatelet regimens. This work 
evidenced that stent implantation was a safe technique without anticoagulant treatment and with the 
administration of dual antiplatelet therapy [24]. This marked the turning point in the establishment of 
stent implantation as a treatment for coronary artery disease. In 1999 they accounted for 84.2% of 
PCI procedures [25]. 
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Inflammation and the era of drug-eluting stents 
After stent implantation, smooth muscle cells (SMC) can undergo a rapid adhesion and 
proliferation also known as in-stent restenosis (ISR). This process causes a narrowing of the vessel 
in an average of 15-20% of patients, being a phenomenon of concern [26]-[28]. DES have proven to 
reduce stenosis, but the risk of late local endothelium regeneration events and late stent thrombotic 
(LAST) events are still present and can affect clinical long-term implantation [29]-[31]. Previous 
studies have demonstrated that the migration and proliferation of SMCs induced by injury and the 
delay of re-endothelialization comprise the major events which lead to neointima formation. 
Endothelium has an important role maintaining the integrity of the vessel by preventing thrombosis 
and hyperplasia during regeneration. Rapid re-endothelization has proven to contribute with a correct 
healing of the tissue avoiding ISR and LAST [32]-[34]. 
At early stages of restenosis, platelet activation and thrombosis take place at the affected area 
accompanied by the recruitment of monocytes, neutrophils and lymphocytes. The main problem 
derived from this is the hyperplastic response of medial vascular smooth muscle cells (VSMC) caused 
by the chemotactic and mitogenic factors produced by neointimal cells. These VSMC migrate to the 
growing neointima and exhibit a high proliferative activity as seen in Figure 4. VSMC are normally 
fusiform and show a differentiated contractile phenotype which is characterized by a reduced 
proliferative activity. On the other hand, activated VSMC found on injured vessels have an 
undifferentiated phenotype which shows broader and flatter shapes. They are characterized by the 
expression of embryonic isoforms of contractile proteins, high proliferation and responsiveness to 
growth and chemotactic stimuli. After these initial stages, inflammation starts to recede as a sign of 
the restoration of the contractile phenotype of neointimal VSMC. This leads to normalization of the 
composition of the extracellular matrix leading to a final stage where the vessel wall is restored [35]. 
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Figure 4:Diagram illustrating restenosis development in a vessel after stenting. Left part of the image 
shows a vertical section of a target vessel right after stenting. Center of the image shows a horizontal 
section of the vessel with the representation of early and late phases of restenosis development with 
the different cell types involved. Right part shows late phase restenosis on a vertical section of a 
vessel. Changes in VSMC phenotype are depicted with a clear lumen reduction process seen from left 
to right.  Adapted from [36]. 
Together with the risk of subacute thrombosis, the main problem of metal stents was late intra-
stent restenosis linked to multiple factors. A stent acts as a platform preventing acute vascular 
occlusion, removing the elastic recoil and reducing late remodeling. These are some of the main 
factors causing post-balloon restenosis, but proliferation and hyperplasia of the neointima persist after 
implantation and are even stimulated by the stent itself. By the end of the 90s, the incidence of stent 
restenosis ranged from 15 to 30%, and these percentages were greater in the groups of higher risk 
patients. These are specifically those with lesions in small vessels, long and/or bifurcation lesions, 
patients with diabetes mellitus, etc.  
The attempt to minimize hyperplasia of the neointima caused by stent implantation and thus 
reduce repetitive revascularization led to the development of another revolutionary treatment concept: 
The drug-eluting stent or DES [16]. These types of stents contain antiproliferative drugs which are 
released from a polymer carrier, regulating the pharmacological release rate. The mechanism of 
action of the drug released focuses on the inhibition of smooth muscle cell growth, the main 
component of intimal hyperplasia. The first DES to be developed were the Taxus and Cypher stents, 
incorporating paclitaxel and sirolimus, respectively. Both stents demonstrated a marked reduction in 
restenosis compared to BMS stents, without inhibiting it (TAXUS I, II, II and IV, SIRIUS, E- SIRIUS 
and C-SIRIUS studies) [37]-[40]. 
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The observed reduction in the restenosis rates, as compared to BMS, was the driving force 
which provided the greatest exponential growth of PCI as a treatment for patients with coronary artery 
disease (CAD). However, in 2006, serious doubts were raised on the safety profile of these stents, 
as results of studies reporting a slight increase in late thrombosis and late mortality associated with 
the use of drug-eluting stents were published [41][42]. Late stent thrombosis is a multifactorial 
process, but it is clearly related to the presence of polymer in the vascular wall which causes a healing 
delay favoring the formation of a thrombus with fatal consequences.  
Although the increase in late stent thrombosis was not statistically significant and the results 
published in subsequent years indicated contradictory data, these concerns were a vital stimulus in 
guiding the investigation and have ultimately led to the development of second generations stents. 
These are loaded with new drugs such as everolimus, biolimus or zotarolimus, and new platforms: 
CoCr, PtCr, and more biocompatible and reabsorbable polymers or polymer-free platforms [16]. As 
the risk of thrombosis is minimized with the prolongation of dual antiplatelet therapy for one year, its 
use started to be recommended in the 2011 ACCF/AHA/SCAI PCI Guideline for Percutaneous 
Coronary Intervention [24]. 
The latest advances in DES use reabsorbable polymers or even polymer-free platforms that 
directly release the drug, with the aim of improving their integration into the vascular wall and thereby 
reducing the incidence of late thrombosis. Furthermore, fully reabsorbable stents have been 
developed. The favorable results obtained with DES, when applying the recommended antiplatelet 
regime, has led to the predominance of their use in PCI and is now an accepted treatment for patients 
with a high risk of developing restenosis. This patients usually suffer from diseases such as diabetes, 
myocardial infarction and complex  CAD, as well as risk lesions, such as vessels of small diameter, 
lesions in bifurcation, arteries with restenosis, saphenous vein graft (bypass, CAGB), left coronary 
trunk, etc. [24][43]–[47] 
Up to this point a main issue has been described which will lead to the main objective of this 
thesis. In order to treat CAD, DES are commonly used, although their designs are not optimum and 
can be improved in order to reduce restenosis. Being so, the main objective of this thesis becomes 
the design and development of new types of stents which, through tailored drug release, aim to 
minimize the actual inflammatory response derived from medical device implantations. 
The next section will focus on some key points which will be discussed throughout this thesis. 
In order to do so, some questions should be put forward: Why is the design of a stent so important? 
Do the polymers used influence their performance? Is there a unique optimum design for stents? 
Following next, these issues are addressed in order to narrow the focus of this introduction and to 
present the next chapters. 
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Importance of the design and materials which compose a stent 
The stent is a mechanical device that keeps the vascular lumen open via a vessel scaffold. The 
shape, thickness, coating and selection of the material are some of the factors that need to be 
considered in the design of the device, since subtle differences can lead to completely different 
medical results. In an ideal design of a stent and its carrier matrix, all the following aspects need to 
be considered:  
• Ease of use
• Wide range of sizes
• Low profile with ability to cross severe stenosis
• Firm adherence to the balloon
• High expandability with no length changes
• Uniform scaffold of the vessel without obstruction of the lateral branches, with good
conformability to vessel angulations, which must also be recrossable, with a good cell opening
capacity.
The material must be biocompatible, resistant to corrosion, migration and extrinsic compression 
(radial force), must not show permanent deformability or degradation over time and must show 
radiopacity to be viewed by fluoroscopy. In particular, corrosion is a critical parameter. High 
concentration of cell chloride creates a particularly corrosive environment, which is known to be the 
principal cause of stent fracture [48]. 
The design of the stent is defined by the pattern, if any, which has been cut off from the cylindrical 
strut. Strategies used vary from a tubular shape obtained by laser cut to the obtention of different 
patterns derived from one or several wires with a sinusoid and joined crowns (Figure 5). Most 
coronary stents used at the moment develop their design from the first strategy, a tube shaped by 
laser cut. Closed designs provide a better coverage to the luminal surface and greater scaffold to the 
vessel due to a higher radial force. This structure is also less flexible and makes it difficult to access 
winding and calcified lesions. Open designs provide a greater stent flexibility and easier access to 
winding, calcified lesions and lateral branches. On the other hand, the radial force is lower as well as 
the coverage of the luminal opening. 
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To improve flexibility in the new designs, the number of crowns has been increased as this is 
associated with a reduction in the length and thickness of the strut (wire). Currently, the geometry of 
the strut section has been largely improved compared with initial models. Many have a circular or 
round section rather than a rectangular one with more acute edges. This shape modification was 
done to minimize lesions in the vascular wall during implantation [16].  
Figure 5: Design of coronary stents. This flow chart shows the main structure designs used to elaborate stents. Starting 
with Tubular and coil structures, the first one is commonly used with closed or open structures. Some examples of 
commercial stents are presented under each cell structure. 
Results from studies performed in vitro and in vivo with animals have shown that the lower the 
thickness of the wire, the better the endothelialization and the lower the restenosis due to reduced 
trauma in the vascular wall [49][50]. These findings are confirmed in the ISAR-STEREO clinical trial, 
which show that a lower strut thickness induces less restenosis [51].  
Research also shows that the strut thickness is related to the susceptibility of thrombi formation 
and risk of stent thrombosis [52]. New generation stents have focused on the reduction of the cross 
profile, reduction of strut thickness and improved flexibility. 
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The alloys most commonly used in coronary stents are made either of stainless steel, which 
were the first available stents, or cobalt chrome (CoCr). The first stents were made of stainless Steel, 
widely used, but more and more these alloys have been replaced by CoCr (2nd generation bare metal 
coronary stents, and new DES), the most widely used up to date [16]. The CoCr alloy is 45% stronger 
than stainless steel, allowing reduction of the strut thickness maintaining the radial force, increasing 
stent flexibility and navigability. In addition, it is more resistant to fatigue and corrosion and due to the 
higher material density, it is more radiopaque. The first CoCr stents placed on the market with a high 
relevance in their clinical use are the Multilink Vision stent from Abbott Laboratories, made of CoCr 
L605, and the Driver stent from Medtronic, made of CoCr F562. Both have a similar wire thickness 
and comparable clinical results showing no inferiority when compared to stainless steel stents 
[53][54]. 
On the other hand, it is also of high importance to use a biocompatible material for stent 
production. Lower biocompatibility of the stent strut is related to thrombogenesis and the inflammatory 
reaction, which in turn favors thrombogenesis and neointimal proliferation (restenosis). On the other 
hand, a greater biocompatibility promotes endothelization and healing of the arterial wall.  
In addition, new stent designs with novel alloys, other than stainless steel, allow an area 
reduction (thin strut) in contact with the body after implantation. Different coatings and surface 
treatments (inertization) have also been developed with the intention to minimize ion release from the 
platform. These approaches have led to biocompatibility improvement and increased resistance of 
the struts. Some examples are stents based on silicon carbide, turbostatic carbon/diamond-like 
carbon (DLC, Chrono stent (Sorin)), titanium nitride (Titan BAS stent (Hexacat)), silicon carbide (Pro-
kinetic stent (Biotronik)) or ion implantation (ICROS stent (amg)). 
So far, a type of strut as well as a combination of biocompatible polymers will have to be selected 
to produce the new stent designs in this thesis. To produce our tailored designs, it is necessary to 
develop suitable coating techniques and analytical methodology which allow the elaboration and 
characterization of designed stents. To address this issue, Chapter II will focus on the development 
of the required techniques and methodologies. This will enable the proposal of new types of coatings 
and will produce the first DES which will be elaborated in this thesis. 
Following, clinical use of drug eluting stents will be discussed to understand why there is no 
single unique solution for DES. 
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Clinical use of coronary stents and the search for an optimum design 
The use of DES is recommended both in simple and complex lesions and in low and high-risk 
patients, but in general the difference in efficacy between DES and BMS appears to be higher in 
complex lesions and in patients at risk. 
However, it must be considered that the greatest inconvenience of DES is the need for 
prolonged antiplatelet therapy of at least 1 year, to prevent the risk of late stent thrombosis, as well 
as its cost, which is significantly higher than that of BMS stents. On the other hand, the designs of 
the new BMS stents have allowed a significant reduction in the strut thickness (thin-strut), a critical 
factor in the development of restenosis, the use of more biocompatible materials and, in some cases 
have included surface treatments that improve biocompatibility (inertization). These innovations have 
been translated into an improvement of vascular response compared with the original stents [51][55]. 
The 2011 ACCF-AHA-SCAI Guideline for Percutaneous Coronary Intervention [24] has 
established the recommendations for use of coronary stents based on the level of evidence of the 
benefit-risk for the patient, established in the multiple randomized, controlled trials (RTC) performed 
with BMS and DES stents, which are as follows: 
• Before implanting a DES, it must be ensured that the patient will be able to tolerate the prolonged
antiplatelet treatment (dual antiplatelet therapy, DAPT) for at least 12 months.
• DES are useful as an alternative to BMS stents to reduce the risk of restenosis in cases where
the risk of restenosis is increased, and it is likely that the patients can tolerate and comply with
the prolonged DAPT treatment.
• The use of BMS stents should occur in patients with a high risk of bleeding, who are unable to
comply with the DAPT treatment for at least 12 months, or who have scheduled an invasive
and/or surgical procedure for the following 12 months that would require discontinuing DAPT
treatment.
• DES coronary stents should not be used in patients where it is likely that they will not tolerate
and comply with prolonged DAPT treatment for at least 12 months or where this cannot be
established before implantation.
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Therefore, it can be concluded that considering the variety of designs, characteristics and 
types of stents, BMS and DES, and in particular the clinical results obtained in the studies performed 
with different stents, the experts consider that there is no single stent design, type of polymer or 
adequate drug for all patients and types of lesions. As a result, a more individualized selection of the 
stent considering the characteristics of the patient will be translated into an improvement in clinical 
safety and efficacy in the long term. 
If there is no unique solution for DES designs, then the problem should be addressed slightly 
different. In order to produce a desired drug release profile, a complete understanding and tailoring 
of the elution phenomenon from a designed polymeric matrix is needed. To address this, Chapter III 
will focus on the selection of various biodegradable polymers and antiproliferative drugs to produce 
a set of experiments which will enable complete control of drug elution. The sublimation of this work 
will produce a novel tailored multilayered DES ready to be used.  
Next, a brief background is given on how the development of new concept/formulations for 
DES will be carried out in a research laboratory.  
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Development of new concept/formulations for DES elaborated in research 
laboratories  
 
 As seen, a key factor to take in account in order to reduce proliferation and hyperplasia of the 
neointima has proven to be the polymeric matrix in which the drug is embedded, which will affect the 
recovery of the patient. This leads to the development of new coating strategies and new polymers 
which will not cause, or will at least diminish, these negative effects when they are in contact with 
intima and neointima [56]–[58].This has led to the development and testing of biodegradable and 
multicoated stent, [56][58][59] among other types, to achieve an improved healing behavior seen in 
clinical trials such as ABSORB [60]. As previously discussed, new DES designs need to balance the 
amount of antiproliferative drug released so the endothelization and cicatrization are not affected. 
Some DES have applied an interesting approach based on the coating of their abluminal part enabling 
the drug to be released directly on the arterial wall, while the part in contact with the blood stream is 
only bare metal [61][62]. Polymer matrix, drug elution and stent design are key factors which have to 
be taken in account while developing new stents. 
 On the other hand, these types of DES are usually fabricated with industrial sprayers or 
through dipping techniques, which must be tailored to assure good coating results. These stents also 
must be characterized to compare them with other gold standards and to detail their complex 
composition.  
The promising results achieved up to date on clinical trials and the need to develop better 
solutions for these current problems have encouraged the elaboration of this thesis. Having all this in 
mind, a new type of stent coating is going to be designed in order to reduce the inflammatory response 
seen in common DES. This thesis will start with the characterization of market standard stents to help 
build a background which will enable useful coating designs. Knowing which compositions are going 
to be pursued, the next chapter will focus on the elaboration of the necessary equipment and 
techniques to create novel coatings. From this point on, the next two chapters focus on the study of 
the releases obtained from the different layer designs elaborated in our laboratory. As the reader may 
notice through this last part of the thesis, a wide variety of profiles and various eluting phenomenon 
are described, opening new possibilities for tailored drug delivery. 
  
Chapter I 
16 
Gene therapy and its role in the treatment of restenosis after stent 
implantation. 
Over the last decade gene therapy has emerged as a novel, viable and promising approach to 
prevent restenosis. Based on local delivery of therapeutic agents to a target site, gene therapy 
proposes a biological solution to growth of intimal mass or vascular wall remodelling [63]. Gene 
therapeutic strategies offer novel treatment methods to promote re-endothelialization, and inhibit 
inflammation, neointimal hyperplasia and late stent thrombosis [64]-[67].  
The translation of gene therapy into clinical application must be safe and requires an effective, 
site-specific delivery system as well as the ability to provide sustained transgene expression. Some 
examples of the application of this strategy can be seen in the development of treatments with an 
antibody to the platelet fibrinogen receptor (glycoprotein IIb/IIIa or integrin αIIb/βIII) [68], platelet-
derived growth factor (PDGF) antagonist tradipil [69] or the anti-oxidant probucol [70] which reduced 
restenosis rate to 15 - 20%. In both the Stent Restenosis Study (STRESS) and Belgian Netherlands 
Stent Study (BENESTENT) trials, intracoronary stent placement reduced restenosis rates to 15% 
[71][72]. 
As discussed throughout this chapter, the development of new technologies/strategies and the 
use of novel drugs can improve stenting, but they leave room for complimentary therapies that could 
further decrease restenosis or eliminate it entirely. This achievement would make coronary 
interventions become a cure for symptomatic stenoses rather than merely a temporizing procedure. 
Against this background, gene therapy has emerged as a promising approach aimed at modification 
of cellular processes that give rise to restenosis [73]. 
This thesis was designed to take one last step, aiming to produce on more type of novel coating. 
As addressed in this introduction, gene therapy is a parallel line of work which can lead to the 
reduction or elimination of restenosis. Most important, this strategy can also be used to produce a 
tailored release. Aiming for a richer approach for restenosis treatment throughout this thesis, Chapter 
IV will tackle a novel stent design which will use a polymeric coating to adhere nanocarriers.  
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2. Aims
This thesis has focused on treating CAD, which remains the leading cause of death in many 
countries.  The main challenge discussed, is improving CAD treatment through restenosis reduction. 
This is achieved by the elaboration of tailored pharmacological releases and the design of 
mechanisms which enable gene therapies and antirestenotic agents to be deployed in a controlled 
manner.   
A work plan is performed to achieve this goal, which starts with the development of coating 
techniques and analytical methodologies. These will render the possibility of producing our own 
tailored coatings and the chance of experimenting with them, charting the influence of several 
parameters which directly influence drug deployment. Next, this work presents two different paths 
which can be followed to achieve restenosis reduction in stent implantation.  
First, experimentation is focused on producing a novel multilayered stent which aims to reduce 
restenosis through tailored drug release. After, a second and final approach is presented, through the 
elaboration of a coating which immobilizes loaded nanoparticles aimed for gene therapy. After 
completing this workplan, a final chapter closes this thesis with the conclusions drawn from all the 
experimentation. 
Following, the aims of each chapter are presented. 
The main objective of this thesis is to design and develop new types of stents which, through 
tailored drug release, aim to minimize the actual inflammatory response derived from medical device 
implantations. 
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The goals of the present thesis can be summarized in the following points: 
- Development of suitable coating techniques and an analytical methodology that allows the 
elaboration and characterization of designed stents. This will enable the proposal of new 
types of coatings and will produce the first DES which will be elaborated in this thesis (chapter 
II). 
- Using the techniques tuned in the previous chapter, a variety of DES will be produced, and 
their release will be characterized to achieve different profiles. The main goal of this chapter 
is to achieve complete control of drug release in order to produce a target type of stent which 
will be designed to perform with a designed release profile. This stent will be tested in an in-
vivo trial to check its efficacy (chapter III).  
- After achieving the desired release control through the creation of tailored polymeric layers, 
this thesis was planned to make one last step towards novel coatings for DES. Inspired by 
nanoparticle coatings used recently in DES, a new proposal is made. To achieve a new 
design, a novel polymer for DES is used and an original way to adhere nanocarriers is 
tailored. The goal of this chapter is to develop a strategy to coat stents with nanocarriers 
which can show a good adhesion and avoid the washing away of the nanoparticles when 
deployed (Chapter IV). 
Introduction to coronary artery disease and therapeutic strategies for its treatment 
19 
3. References
[1] CDC, “Division for Heart Disease and Stroke Prevention,” 2018. [Online]. Available: 
https://www.cdc.gov/dhdsp/. 
[2] CDC, “National Center for Chronic Disease Prevention and Health Promotion,” 2018. 
[Online]. Available: https://www.cdc.gov/chronicdisease/index.htm. 
[3] H. GK., “Inflammation, atherosclerosis, and coronary artery disease,” N. Engl. J. 
Med., pp. 1685–1695, 2005. 
[4] American Heart Society, “Angina (Chest Pain).” 2020. [Online]. Available: 
https://www.heart.org/en/health-topics/heart-attack/angina-chest-pain 
[5] MedlinePlus, “Angina de pecho.” 2020. [Online]. Available: 
https://medlineplus.gov/spanish/angina.html. 
[6] J. I. Weitz, J. W. Eikelboom, and M. M. Samama, “New antithrombotic drugs - 
Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of 
Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, no. 2 
SUPPL., 2012. 
[7] P. F. Cohn, “Pharmacological treatment of ischaemic heart disease Monotherapy vs 
combination therapy,” Eur. Heart J., vol. 18 Suppl B, no. July, pp. B27-34, 1997. 
[8] UCSF, “Coronary Artery Bypass Grafting (CABG),” 2020. [Online]. Available: 
https://cardiacsurgery.ucsf.edu/conditions--procedures/coronary-artery-bypass-
grafting-(cabg).aspx. 
[9] Ter Woorst, J., Sjatskig, J., Soliman‐Hamad, M., Akca, F., Haanschoten, M., & van 
Straten, A. (2020). Evolution of perioperative blood transfusion practice after coronary 
artery bypass grafting in the past two decades. Journal of Cardiac Surgery. 
[10] Heart&Stroke, “Percutaneous coronary intervention (PCI or angioplasty with stent),” 
2020. [Online]. Available: http://www.heartandstroke.ca/heart/treatments/surgery-
and-other-procedures/percutaneous-coronary-intervention. 
[11] C. T. Dotter and M. P. Judkins, “Percutaneous Transluminal Treatment of 
Arteriosclerotic Obstruction.,” Radiology, vol. 84, no. November, pp. 631–643, 1965. 
[12] W. S. Garg S, R.L., Serruys PW, “Coronary artery stents.,” in The PCR-EAPCI 
Textbook Percutaneous interventional cardiovascular medicine., 2012. 
[13] isic, “The indonesian society of interventional cardiology.” 2020. [Online]. Available: 
http://www.isic.or.id/patient_education_and_collaboration/2014/11/mengenal_lebih_
dekat_stent_jantung_1. 
Chapter I 
20 
 
[14] C. Casey, “Multi-vessel coronary disease and percutaneous coronary intervention,” 
Heart, vol. 90, no. 3, pp. 341–346, 2004. 
[15] C. T. Dotter, R. W. Buschmann, M. K. McKinney, and J. Rösch, “Transluminal 
expandable nitinol coil stent grafting: preliminary report.,” Radiology, vol. 147, no. 1, 
pp. 259–260, 1983. 
[16] V. A. P. Ma Pilar Guillén Goberna, Purifiación Mogollón Cardero, Inés Lago Celada, 
“Procedimientos Intervencionistas,” Man. Enfermería en Cardiol. Interv. y 
Hemodinámica. Protoc. unificados, pp. 188–238, 2014. 
[17] J. C. Palmaz, R. R. Sibbitt, S. R. Reuter, F. O. Tio, and W. J. Rice, “Expandable 
intraluminal graft: a preliminary study. Work in progress.,” Radiology, vol. 156, no. 1, 
pp. 73–77, 1985. 
[18] R. A. Schatz, J. C. Palmaz, F. O. Tio, F. Garcia, O. Garcia, and S. R. Reuter, “Balloon-
expandable intracoronary stents in the adult dog,” Circulation, vol. 76, no. 2, pp. 450–
457, 1987. 
[19] A. Colombo, P. Hall, J. Thomas, Y. Almagor, and L. Finci, “Initial Experience With the 
Disart icu lated ( One-Half ) Palmaz-Schatz Stent : A Technical Report,” vol. 308, pp. 
15–19, 1992. 
[20] Scgvs, “P.A.D / Cath Lab,” 2020. [Online]. Available: 
https://www.scgvs.com/contents/patient-resources/pad-cath-lab. 
[21] P. W. Serruys et al., “Randomised comparison of implantation of heparin-coated 
stents with balloon angioplasty in selected patients with coronary artery disease 
(Benestent II)[erratum appears in Lancet 1998 Oct 31;352(9138):1478],” Lancet, vol. 
352, no. Benestent II, pp. 673–681, 1998. 
[22] Piccolo, R., & Windecker, S. (2018). Stent Technology. In The Interventional 
Cardiology Training Manual (pp. 137-159). Springer, Cham. 
[23] Fischman, D. L., Leon, M. B., Baim, D. S., Schatz, R. A., Savage, M. P., Penn, I., ... 
& Cleman, M. (1994). A randomized comparison of coronary-stent placement and 
balloon angioplasty in the treatment of coronary artery disease. New England Journal 
of Medicine, 331(8), 496-501. 
[24] G. N. Levine et al., “2011 ACCF/AHA/SCAI guideline for percutaneous coronary 
intervention,” J. Am. Coll. Cardiol., vol. 58, no. 24, pp. e44–e122, 2011. 
[25] D. R. Holmes et al., “Results of prevention of REStenosis with tranilast and its 
outcomes (PRESTO) trial,” Circulation, vol. 106, no. 10, pp. 1243–1250, 2002. 
 
Introduction to coronary artery disease and therapeutic strategies for its treatment 
21 
[26] C. A. Kavanagh, Y. A. Rochev, W. M. Gallagher, K. A. Dawson, and A. K. Keenan, 
“Local drug delivery in restenosis injury: Thermoresponsive co-polymers as potential 
drug delivery systems,” Pharmacol. Ther., vol. 102, no. 1, pp. 1–15, 2004. 
[27] Katsanos, K., Kitrou, P., Spiliopoulos, S., Diamantopoulos, A., & Karnabatidis, D. 
(2016). Comparative effectiveness of plain balloon angioplasty, bare metal stents, 
drug-coated balloons, and drug-eluting stents for the treatment of infrapopliteal artery 
disease: systematic review and Bayesian network meta-analysis of randomized 
controlled trials. Journal of Endovascular Therapy, 23(6), 851-863. 
[28] T. C. Woods and A. R. Marks, “Drug-Eluting Stents,” Annu. Rev. Med., vol. 55, no. 1, 
pp. 169–178, 2004. 
[29] G. Acharya and K. Park, “Mechanisms of controlled drug release from drug-eluting 
stents,” Adv. Drug Deliv. Rev., vol. 58, no. 3, pp. 387–401, 2006. 
[30] Kang, S. H., Chae, I. H., Park, J. J., Lee, H. S., Kang, D. Y., Hwang, S. S., ... & Kim, 
H. S. (2016). Stent thrombosis with drug-eluting stents and bioresorbable scaffolds: 
evidence from a network meta-analysis of 147 trials. JACC: Cardiovascular 
Interventions, 9(12), 1203-1212. 
[31] S. Venkatraman, F. Boey, and L. L. Lao, “Implanted cardiovascular polymers: Natural, 
synthetic and bio-inspired,” Prog. Polym. Sci., vol. 33, no. 9, pp. 853–874, 2008. 
[32] A. de Mel, G. Jell, M. M. Stevens, and A. M. Seifalian, “Biofunctionalization of 
biomaterials for accelerated in situ endothelialization: A review,” Biomacromolecules, 
vol. 9, no. 11, pp. 2969–2979, 2008. 
[33] S. Meng et al., “The effect of a layer-by-layer chitosan-heparin coating on the 
endothelialization and coagulation properties of a coronary stent system,” 
Biomaterials, vol. 30, no. 12, pp. 2276–2283, 2009. 
[34] Q. Lin, X. Ding, F. Qiu, X. Song, G. Fu, and J. Ji, “In situ endothelialization of 
intravascular stents coated with an anti-CD34 antibody functionalized heparin-
collagen multilayer,” Biomaterials, vol. 31, no. 14, pp. 4017–4025, 2010. 
[35] M. A. Costa and D. I. Simon, “Molecular basis of restenosis and drug-eluting stents,” 
Circulation, vol. 111, no. 17, pp. 2257–2273, 2005. 
[36] A. V., “Modulating the proliferative response to treat restenosis after vascular injury, 
in Molecular and Translational Vascular Medicine.,” in Modulating the proliferative 
response to treat restenosis after vascular injury, in Molecular and Translational 
Vascular Medicine., Springer, 2012, pp. 228–248. 
Chapter I 
22 
[37] E. Schampaert et al., “The Canadian study of the sirolimus-eluting stent in the 
treatment of patients with long de novo lesions in small native coronary arteries (C-
SIRIUS),” J. Am. Coll. Cardiol., vol. 43, no. 6, pp. 1110–1115, 2004. 
[38] J. Schofer et al., “Sirolimus-eluting stents for treatment of patients with long 
atherosclerotic lesions in small coronary arteries: Double-blind, randomised 
controlled trial (E-SIRIUS),” Lancet, vol. 362, no. 9390, pp. 1093–1099, 2003. 
[39] D. R. Holmes et al., “Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial: A 
Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at 
High Risk for Coronary Restenosis,” Circulation, vol. 109, no. 5, pp. 634–640, 2004. 
[40] A. Halkin and G. W. Stone, “Polymer-based paclitaxel-eluting stents in percutaneous 
coronary intervention: A review of the TAXUS trials,” J. Interv. Cardiol., vol. 17, no. 5, 
pp. 271–282, 2004. 
[41] D. Stents, G. M. Sangiorgi, and G. Stankovic, “Incidence, Predictors, and Outcome 
of Thrombosis After Successful Implantation of Drug-Eluting Stents,” vol. 293, no. 17, 
2005. 
[42] R. Moreno et al., “Drug-eluting stent thrombosis: Results from a pooled analysis 
including 10 randomized studies,” J. Am. Coll. Cardiol., vol. 45, no. 6, pp. 954–959, 
2005. 
[43] H. V. Anderson and T. D. Henry, “Drug-Eluting or Bare-Metal Stents for Acute 
Myocardial Infarction,” vol. 49, no. 19, pp. 7–9, 2007. 
[44] J. Mehilli et al., “Drug-eluting versus bare-metal stents in saphenous vein graft lesions 
(ISAR-CABG): A randomised controlled superiority trial,” Lancet, vol. 378, no. 9796, 
pp. 1071–1078, 2011. 
[45] G. W. Stone et al., “Paclitaxel-eluting stents versus bare-metal stents in acute 
myocardial infarction,” N.Engl.J.Med., vol. 360, no. 1533-4406 (Electronic), pp. 1946–
1959, 2009. 
[46] P. W. Serruys, P. A. Lemos, and B. A. Van Hout, “Sirolimus eluting stent implantation 
for patients with multivessel disease: Rationale for the arterial revascularisation 
therapies study part II (ARTS II),” Heart, vol. 90, no. 9, pp. 995–998, 2004. 
[47] A. T. L. Ong et al., “The unrestricted use of paclitaxel- versus sirolimus-eluting stents 
for coronary artery disease in an unselected population: One-year results of the 
Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry,” J. 
Am. Coll. Cardiol., vol. 45, no. 7, pp. 1135–1141, 2005. 
Introduction to coronary artery disease and therapeutic strategies for its treatment 
23 
[48] D. R. Whittaker and M. F. Fillinger, “Vascular and Endovascular Surgery The 
Engineering of Endovascular Stent Technology : A Review,” vol. 40, no. 2, pp. 85–94, 
2006. 
[49] R. Jabara et al., “A third generation ultra-thin strut cobalt chromium stent: 
Histopathological evaluation in porcine coronary arteries,” EuroIntervention, vol. 5, 
no. 5, pp. 619–626, 2009. 
[50] C. Rogers and E. R. Edelman, “Endovascular stent design dictates experimental 
restenosis and thrombosis.,” Circ. J., vol. 91, no. 12, pp. 2995–3001, 1995. 
[51] J. Pache et al., “Intracoronary stenting and angiographic results: Strut thickness effect 
on restenosis outcome (ISAR-STEREO-2) trial,” J. Am. Coll. Cardiol., vol. 41, no. 8, 
pp. 1283–1288, 2003. 
[52] A. Manuscript and T. Structures, “NIH Public Access,” vol. 6, no. 13, pp. 247–253, 
2009. 
[53] D. J. Kereiakes et al., “Usefulness of a cobalt chromium coronary stent alloy,” Am. J. 
Cardiol., vol. 92, no. 4, pp. 463–466, 2003. 
[54] M. H. Sketch, M. Ball, B. Rutherford, J. J. Popma, C. Russell, and D. J. Kereiakes, 
“Evaluation of the Medtronic (Driver) cobalt-chromium alloy coronary stent system,” 
Am. J. Cardiol., vol. 95, no. 1, pp. 8–12, 2005. 
[55] CX charing cross, “Multilayer stent not a breakthrough, say 56% of CX audience.” 
[56] S. Youssefian and N. Rahbar, “Nano-scale adhesion in multilayered drug eluting 
stents,” J. Mech. Behav. Biomed. Mater., vol. 18, pp. 1–11, 2013. 
[57] S. (CN) Yi Zhang, Shanghai (CN); Qiyi Luo, Shanghai (CN); Zhirong Tang, Shanghai 
(CA); Junfei Li, “DRUG-ELUTING STENT WITH MULTI-LAYER COATINGS,” US 
2005/0033414A1, 2005. 
[58] L. C. Su, Y. H. Chen, and M. C. Chen, “Dual drug-eluting stents coated with 
multilayers of hydrophobic heparin and sirolimus,” ACS Appl. Mater. Interfaces, vol. 
5, no. 24, pp. 12944–12953, 2013. 
[59] X. Wang, S. S. Venkatraman, F. Y. C. Boey, J. S. C. Loo, and L. P. Tan, “Controlled 
release of sirolimus from a multilayered PLGA stent matrix,” Biomaterials, vol. 27, no. 
32, pp. 5588–5595, 2006. 
[60] A. Colombo and A. S. Sharp, “The bioabsorbable stent as a virtual prosthesis,” 
Lancet, vol. 373, no. 9667, pp. 869–870, 2009. 
Chapter I 
24 
[61] A. Abizaid and J. R. Costa, “New drug-eluting stents an overview on biodegradable 
and polymer-free next-generation stent systems,” Circ. Cardiovasc. Interv., vol. 3, no. 
4, pp. 384–393, 2010. 
[62] S. Garg and P. W. Serruys, “Coronary stents: Current status,” J. Am. Coll. Cardiol., 
vol. 56, no. 10 SUPPL., pp. S1–S42, 2010. 
[63] P. Holvoet, R. Quarck, and P. Holvoet, “Restenosis and gene therapy,” Ashley Publ., 
no. February, 2001. 
[64] K. Yin and D. K. Agrawal, “Gene therapy for in-stent restenosis : Targets and delivery 
system,” vol. 1, no. 2, pp. 93–101, 2014. 
[65] P. Jarkko, “Local adventitial anti-angiogenic gene therapy reduces growth of vasa-
vasorum and in-stent restenosis in WHHL rabbits,” 2018. 
[66] S. Ylä-Herttuala and A. H. Baker, “Cardiovascular Gene Therapy: Past, Present, and 
Future,” Mol. Ther., vol. 25, no. 5, pp. 1095–1106, 2017. 
[67] W. Ye et al., “Reduction-Responsive Nucleic Acid Delivery Systems To Prevent In- 
Stent Restenosis in Rabbits,” ACS Appl. Mater. Interfaces, vol. 11, pp. 28307–28316, 
2019. 
[68] S. Francisco and I. D. State-of-the-art, “Randomised trial of coronary intervention with 
antibody against platelet IIb / IIIa iritegrin for reduction of clinical restenosis : results 
at six months *,” pp. 881–886, 1993. 
[69] A. Maresta et al., “Trapidil ( Triazolopyrimidine ), a Platelet-Derived Growth Factor 
Antagonist , Reduces Restenosis After Percutaneous Transluminal Coronary 
Angioplast Results of the Randomized , Double-Blind STARC Study,” no. April 1990, 
pp. 2710–2715, 1992. 
[70] M. D. JEAN-CLAUDE TARDIF, M.D., GILLES CÔTÉ, M.D., JACQUES 
LESPÉRANCE, M.D., MARTIAL BOURASSA, M. D. JEAN LAMBERT, PH.D., 
SERGE DOUCET, M.D., LUC BILODEAU, M.D., STANLEY NATTEL, M.D., AND 
PIERRE DE GUISE, and F. T. M. A. P. S. GROUP, “Probucol and multivitamins in 
the prevention of restenosis after coronary angioplasty,” N. Engl. J. Med., vol. 337, 
no. 6, pp. 365–372, 1997. 
[71] Fischman, D. L., Leon, M. B., Baim, D. S., Schatz, R. A., Savage, M. P., Penn, I., ... 
& Cleman, M. (1994). A randomized comparison of coronary-stent placement and 
balloon angioplasty in the treatment of coronary artery disease. New England Journal 
of Medicine, 331(8), 496-501. 
Introduction to coronary artery disease and therapeutic strategies for its treatment 
25 
[72] Serruys, P. W., De Jaegere, P., Kiemeneij, F., Macaya, C., Rutsch, W., Heyndrickx, 
G., ... & Belardi, J. (1994). A comparison of balloon-expandable-stent implantation 
with balloon angioplasty in patients with coronary artery disease. New England 
Journal of Medicine, 331(8), 489-495. 
[73] R. Kishore and D. W. Losordo, “Gene therapy for restenosis : Biological solution to a 
biological problem,” J. Mol. Cell. Cardiol., vol. 42, pp. 461–468, 2007. 
Chapter II. 
Design and production of multi-layered stents 
This page intentionally left blank 
Chapter II 
28 
2.1 Introduction 
This first experimental chapter is based on the elaboration of the first stent models obtained at 
our laboratory. A brief description of the common industrial methods used to produce DES will be 
followed by the characterization techniques and production methods developed throughout the initial 
part of this work. This will help to understand the main issues encountered when producing polymeric 
coatings. At the end of this chapter the first stents obtained are shown, opening a whole range of 
possibilities for the design and creation of new DES. As discussed on chapter I, the whole purpose 
of creating new designs for DES is based on the need to reduce the side effects related to their 
implantation. To achieve effective coating designs, it is necessary to achieve a good understanding 
relative to the composition of the golden standard stents present in the market. This is one of the 
main reasons, apart from characterizing the new stents produced, why the development of analytical 
and characterization methods is so important.  
 Currently, the most used techniques to produce DES in the industry are spraying and dipping. 
Both systems can be appropriate for the elaboration of the new coatings pursued in this thesis, so 
they will be adjusted and applied as to obtain the desired results. To understand these processes 
better they are briefly described next, including the main issues encountered when applying these 
techniques to DES coatings. The two most important techniques used to produce these types of films 
are dipping and spraying. 
Stents are generally coated by dipping or spray coating with polymer and a pharmaceutical agent. 
Dipping consists in the immersion of the stent strut on a mix composed of polymer, drug and solvent. 
Concentration and timings differ with the dipping process used. Some may depend mostly on an 
ultraviolet (UV) curing done afterwards and others may require to be left drying at room temperature 
[1][2]. After a certain period, the stent is slowly pulled out and dried/cured to finish the process. To 
avoid agglomerates or irregular surfaces, relatively low concentration mixes are used [3][4].  
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One of the most common issues encountered while using high concentration mixes is the 
formation of film structures across the open spaces between the filaments of the device. This 
phenomenon is called webbing, and it’s particularly concerning when working with modern stents 
which are designed with less open structures. An incident such as this may interfere with the 
performance of the stent, as entire films may detach. This can be specially dangerous while 
performing a balloon expansion at stent deployment [5]. Films may rupture and provide sites that 
activate platelet deposition or pieces of the bridging film may break off and cause further 
complications such as obstructions in the vessel. In general, dipping techniques are used to coat 
single layers or to create multilayers using different fixing methods such as UV curing [6].  
 Applying a process to coat a medical device using a spray technique usually involves the 
implementation of a polymeric carrier. DES coatings should have a composition which includes a 
solvent, a dissolved polymer, and a therapeutic substance dispersed or dissolved in the mix. After 
applying the mixture to the stent, the solvent is allowed to evaporate. When dry, this process will 
produce a thin layer of polymer mixed with the therapeutic substance over the stent strut [4][7]. 
Depending upon the final coating thickness desired on the stent, a multi-step coating may be applied 
to achieve a multi-layered stent.  
Determined by the solvent used and its volatility, a resting period is required after the spraying 
process. This time may be reduced by applying heat or a gas current to facilitate the evaporation of 
the solvent [8]. An important concept to take in account when spraying an optimal layer is that all 
parameters have to be optimized and fixed. These include distance from the sprayer tip to the stent, 
rotational speed of the stent, horizontal speed of the sprayer, solvent and air flow and polymer and 
drug concentration in the sprayed solution.  
These techniques can prove to be adequate for multiple types of coatings, but in both cases, the 
surface treated is usually activated in some way to enhance adhesion. If the union between coating 
and strut is not good enough, the whole system may detach during stent implementation causing 
serious complications. Next, two of the most well-known methods used to improve adhesion between 
two surfaces are going to be described. 
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 Applying a polymeric matrix may seem the most important part of producing DES, but this 
will render useless if the adhesion between the polymer and the strut is weak. To assure good 
adhesion between them, two methods can prove useful. These are plasma and silanization. 
When applying plasma to modify a selected surface, there are different processes that can be 
considered to achieve satisfactory results. One of these is known as physical sputtering of materials, 
which takes place with a non-reactive gas in the plasma phase. During this process, the atoms which 
compose this gas are turned into ions and accelerated towards the materials surface when achieving 
a plasma phase. When this happens, these ions transfer the energy they store through the collision 
with atoms located on the surface of the material. These atoms will also dissipate this energy to their 
neighbors, and the process will go on until an atom is expelled into the vapor phase [9][10]. This 
sputtering process is used frequently as a cleaning process and is commonly put to practice in the 
glass and ceramic industry. 
 A second method, called chemical etching, involves a chemical reaction of the exited species 
with the elements in the substrate surface. During this process both chemical and physical reactions 
usually take place. These generate superficial modifications which lead to further cross-linking on 
polymers or changes on the hydrophobicity of the recently chemically modified surface [11]–[13]. 
Chemical etching is also largely used as a cleaning process for a wide range of materials. These two 
methods are used throughout Chapter II and III, as they can prepare the stent struts to show a good 
adhesion and hydrophilic behavior. 
 A third type of plasma process, called plasma deposition, is of particular interest. It may be used 
to produce plasma polymerizations, commonly described as “the formation of polymeric materials 
under the influence of plasma” [14]. This involves the dissociation of starting materials and 
reorganization of the resulting neutral and charged molecular fragments into macromolecular 
structures on the surface of the substrate. During this plasma polymerization, a precursor is added 
into the system in order to be activated by plasma to bombard the surface which will lead to the 
dissociation of bonds at the interface, etching and chemical reactions between the active sites in the 
material’s surface and the activated monomer [15]. This method can be used to deposit polymeric 
films over the stent strut and will be studied on Chapter IV. 
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Silanes are commonly known for their use as coupling agents which enhance adhesion between 
inorganic and polymeric materials. After activating the surface through the creation of hydroxyl 
groups, these agents can chemically bond to it and improve adhesion with polymeric coatings [16]. 
Usually, these agents share a common structure R’-Si-X3 where X is a hydrolyzable group which will 
react with the substrate, and R’ a reactive group which bonds to the polymer [17]. 
 Hydrolysis occurs stepwise to form alkoxysilanols and silane triols. Silanol groups are extremely 
reactive and condensation reactions occur easily with silanols on the mineral substrate or with other 
alkoxysilanols [18]. Silanization processes take place through hydrogen bonding when the  silane 
solution is applied to the substrate and by further covalent  M-O-Si oxane bond formation when drying 
[19][20]. This method can provide a quick and easy way to adhere polymeric coatings with no 
specialized instrumentation required. This can be a good method to produce good adhesion for stents 
and will be used throughout Chapter II. 
Now that the processes of activation and coating have been described, the next logical step is 
to comprehend better the composition and design of these films. Following, this introduction will lead 
to how stents are pharmacologically loaded and how can multilayers be achieved. Some main issues 
such as which drug loads should be targeted, or which combinations can produce satisfactory results 
will be tackled. 
In commercial stents, high concentration coatings are one of the preferred means to achieve 
high drug loadings which usually go up to 50% in spraying mixes. These drug loads, once the mix 
is applied and dry on the stent, are usually measured by calculating the µg of drug / surface area 
coated in mm2. Target values are usually over 1 µg/ mm2 [21]–[25].  Depending on the concentration 
of drug or polymer used to spray, the density of the formulation may vary, and the sprayed material 
may produce undesired morphologies over the strut. Multiple dip-coating has been used as a method 
to build thicker coatings on a stent although this has not always been achieved. The application of 
multiple dip coats from low concentration solutions often reach a limiting loading level as equilibrium 
is reached between the solution concentration and the amount of coating deposited [26]. Having this 
in mind it is important to know if the concentrations which are going to be used are suitable for a multi-
layered application.  
 
 
 
 
Chapter II  
32 
 
Various polymers were selected to elaborate the different matrices adhered on the stent struts 
throughout this thesis. PLGA and PLA were the first selected as their release profile was sufficiently 
different and both were well studied and used in commercial stents [27]–[32]. Apart from these two 
polymers, poly(N-(2-hydroxypropyl) methacrylamide) (pHPMA) with a 5% of cholesterol was also 
selected as it had already been elaborated and tested by our group, showing promising results. 
PHPMA is an amphiphilic copolymer that can be used in film-forming compositions. The amphiphilic 
copolymer is characterized by having a defined structure with a hydrophilic polymer backbone and 
pendant hydrophobic groups. When applied to the skin, the copolymer rearranges in contact with the 
lipid-rich domains of the outermost layer of the skin, resulting in stable film formation [33]. Due to its 
characteristics, it may adhere to the artery wall to achieve a control liberation if it has been 
pharmacologically loaded previously. Having these three polymers available, they were used in this 
work to elaborate the different stent coatings.  
These coating systems are usually preceded by surface treatments which enable a good 
adhesion to the stent strut. Using activation procedures previously described in our group and others 
prepared throughout this thesis, an optimal solution will be achieved to enhance adhesion during the 
preparation of the designed stents. In terms of elaborating the different coatings for DES, an 
optimization of spraying and dipping techniques will be done in order to achieve optimum quality 
layers over the stent struts. As described further on throughout this chapter, all methods are going to 
be prepared in order to be used in a laboratory, and later, scaled for industrial use. The main reason 
to build all this methodology and machinery is to have a functional system which allows the production 
of designed stents. As the main objective of this thesis, throughout the elaboration of coatings with 
different mixes of polymers and drugs and the study of their performance, combinations which aim 
for a reduction of restenosis through the design of novel DES are sought. Following, Chapter II will 
focus on the first aim of this thesis as previously described in Chapter I:  
- Development of suitable coating techniques and an analytical methodology that allows the 
elaboration and characterization of designed stents. This will enable the proposal of new types of 
coatings and will produce the first DES which will be elaborated in this thesis. 
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2.2 Materials and methods 
 
Figure 1 presents a diagram of the plasma reactor used in this chapter. An analogical Pirani type 
vacuum meter (MKS, USA) was connected near the middle of the reactor chamber to monitor the 
pressure. In a home-built system, the pulse generator controlled the pulsing of the radio frequency 
signal, which was then treated with a 100W amplifier and passed via an analogue wattmeter and a 
matching network to a 10 cm long coil located around the exterior of the reactor. The typical base 
pressure prior to all experiments was 2x10‐2 mbar. A 50/50 mix of O2 and Ar was used with a final 
working pressure of 8x10-1 mbar. The reactor’s inner volume is approximately 3 L.  Stents activated 
in this reactor were mounted on a metallic filament which suspends the struts in the middle of the 
tubular reactor. Apart from applying 100W, activation was also performed at 120 and 150W. 
Adhesion tests and contact angle results were practically identical for the three methods so an 
activation with 100W was used throughout the thesis to avoid modifying excessively the stent surface. 
 
 
Figure 1: Home‐built 70 cm long cylindrical Pyrex reactor and its electrical components. Ar and O2 flow is regulated and 
added into the reactor chamber through the left entries. Samples are places on top of the crystal sample holder and in the 
interior of the copper coil. A cold trap is situated at the exit to avoid damaging the vacuum pump and to prevent venting the 
gases outside of the system. In the reduction between the faraday cage and the cold trap there is a threaded connection 
which enables the opening/closing of the system in order to introduce or remove samples. System pressure is measured with 
a baratron locates in the reaction chamber and the plasma conditions are fixed with the rest of instrumentation depicted at 
the bottom of the image. 
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Silanization 
 
There are various ways to achieve an adequate coating adhesion to a stent strut. An interesting 
and accessible method can be a silanization process performed after the activation of the metallic 
surface. Testing of different activation methods was carried out with different metallic samples, with 
the same composition as the stents used, placed on different vials. A selection of methods listed next 
were tried out on each sample and evaluated through contact angle and surface inspection using a 
DM2500 microscope from Leica. Some of these techniques are a selection of various well-known 
methods used in our group. Others are a recompilation of different strategies found throughout 
literature [34]–[41]. Next, a list of the techniques used is shown: 
 
• Immersion of the sample in acetone and sonication during 5 min.  
• Immersion of the sample in an EtOH/H2O (1:1) mix for 5 min. Posterior wash with 
ultrapure H2O.  
• Immersion of the sample in H2SO4 5% for 5 min. Posterior wash with ultrapure H2O.    
• Immersion of the sample in HNO3 5% for 5 min followed by an immersion in H2SO4 5% 
for 1 min.  Final wash with ultrapure H2O.  
• Immersion of the sample in H2SO4 20% for 10 min. Posterior wash with ultrapure H2O.    
• Immersion of the sample in H2SO4 20% for 3h. Posterior wash with ultrapure H2O.    
• Immersion of the sample in H2SO4 5% for 10 min followed by an immersion in HNO3 5% 
for 5 min. Posterior wash with ultrapure H2O.    
 
Through the different activation methods, a slight oxidation of the surface followed by the 
presence of water will create rugosities and generate hydroxyl groups attached to the surface. These 
two surface modifications are desirable, as they will enhance adhesion. Hydroxyl groups will react 
with the (3-Aminopropyl)triethoxysilane (3-APTES) as shown in Figure 2, leaving the sample with a 
silanization which will enhance the adhesion of the polymer coating applied over it. This is possible 
due to the bonding with its amine groups which will react with the acid groups found on the polymers 
applied later.  Once each sample is activated, the coating process is carried out through a dipping 
process with 3-APTES at 0.2% during 1 min as described by Chovelon et al [19]. After the samples 
are dry, these are ready to be coated. 
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Figure 2: Process carried out to obtain a silanized surface with 3-APTES. After the activation 
process, hydroxyl groups are attached to the surface as seen on the left. 3-APTES bonds to the 
hydroxyl groups through 3 different sites, releasing EtOH during the reaction.  
Spray technique 
An important part of having a reliable coating technique is the obtention of reproducible and 
repeatable results. To produce good quality coatings that comply with these requirements, a 
functional laboratory spraying machine was built. Starting with the sprayer design, a basic concept 
was drawn to show how it would work. This draft, shown in Figure 3, is used to build a first version 
which became useful to optimize various parameters. A new model is drawn with Solidworks, showing 
a final design which is 3D printed to obtain a final version. This last version was obtained using an 
industrial HP Multi Jet Fusion 4210 3D printer provided by Barel SA. Motors, potentiometers, spray 
nozzle, compressor and power supplies are attached to the final version and the wiring is passed 
through the drilled holes and stored at the bottom of this structure.  
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Figure 3:Elaboration of a lab scale sprayer model. Starting with the image located at the top, a basic concept 
of a laboratory sprayer is depicted. At the upper part of the core structure, a small motor rotates the stents 
while a resistance is used to control the rotation speed. At the bottom, another motor rotates with a gear 
attached to its end which is used to slide the sprayer’s nozzle side-ways following the direction shown by the 
yellow arrow. Under this first image, a dimetric view of the core structure shows indentations made to place 
the motors, circular indentations for the resistances and perforations used to pass all the cables under the 
surface. A tray is designed to slide on one axis through a step design which prevents all other movements. 
Mounted on the tray, a holder is designed to fix the sprayer’s nozzle. On a semicircular mount, a cylindrical 
piece is placed to enable the transmission of the rotation from the motor to a different type of outlet used to 
hold the stents. A last image located at the bottom shows a 3D model printed and ready to be customized. 
Some basic parameters had to be adjusted, such as the distance from the nozzle to the stent, 
the speed of the motors or the flow sprayed through the nozzle. A fan was added to the design later 
on to assure the complete drying of each layer. Following  some guidance from different sources [42], 
[43] parameter intervals are tested until optimal values are achieved. Coating results are checked 
through a DM2500 microscope and SEM imaging. Taking all this into account and after optimizing 
the parameters, the rotation of the upper motor is set to 120 revolutions per minute (rpm) (30-200 
rpm recommended interval [42]) and the bottom motor is set to 24 rpm which creates a linear 
movement of 8 mm/sec (1-30 mm/sec recommended interval [42]). The solid composition in the 
sprayed mixture varies between 1.3 weight percent (%wt.) and 3 %wt. Distance between the nozzle 
and the stent is 2.3 cm and there are 7.5 cm between the stent and the fan. Every stent sprayed later, 
Power supply 
Compressor 
Spray nozzle 
Belt-driven tray 
Core structure 
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with a different parameter, was visually inspected through a microscope. Inspection of samples was 
done to compare the quality of the coatings. 
On the core structure of the sprayer, the rest of components are added as following. Two 100:1 
gear compact motors 1.5 to 3 V DC from Cebekit were attached to the small rectangular slots, each 
connected to a variable resistance. These are connected to a charger and these to a switch to close 
the circuits. Each one was assembled as shown in Figure 3. An extra piece is machined for the top 
motor to separate it from the spraying zone and to change the shape of the rotating output, so it would 
match the mounting support for the stents. 
Spraying mixes were prepared at different concentrations as detailed further on, but the 
combination of solvents and polymers was fixed throughout the thesis. PLA and PLGA were sprayed 
in our lab by mixing them with acetone, while pHPMA was mixed with ethanol. This selection of 
solvents is due to the bad solubility of each polymer with their other respective solvent, thus 
preventing the elimination or fusion with previous sprayed layers when proceeding through a multi-
layer spraying process. These solvents were selected to elaborate the spraying mixes, discarding 
others such as DCM, for safety reasons and due to its easy scale up and industrialization.  
Dipping 
In this thesis, a basic dipping method is set up consisting in the slow immersion of a stent in a 
vial which contains the coating mixture prepared at a concentration of 1% w/v. This stent is attached 
to a thin thread at one of its ends, providing a grip for the user while holding the other end of the 
filament. When immersed in the mixture, the stent is left for 10 seconds before being slowly extracted. 
After a dip, the stent is left hanging from a support during 5 minutes until the layer is dry due to the 
evaporation of the solvent. A schematic example of the process is shown next in Figure 4. 
Figure 4: Dipping process. From left to right, the stent is dipped slowly into the solution and later 
extracted to let dry at room temperature. 
Chapter II  
38 
 
This method has principally a main drawback called webbing, or bridging. To avoid this, some 
modifications are done enabling better results. A modified version of the dip process is carried out in 
this work by making the filament pass through its entire lumen and holding both ends by the user. 
After the dip is done, the user can gently spin the filament by rotating both ends so the excess of 
mixture in the stent will be expelled outwards. When this is done, the stent is dried with a gentle air 
flow to accelerate the process.  
 
Scratch test 
 
 As coating thickness was not going to be the same through the different samples, method A 
was selected from the American Society for Testing and Materials (ASTM) adhesion test D3359 [44]. 
After the coating is dry and ready to be characterized, an x shaped cut is done to the coating with a 
scalpel and the aid of a cutting guide. After doing this, the surface was photographed with a DM2500 
microscope from Leica to obtain an image of the x cut before the adhesion test was done. Next, a 
semitransparent pressure sensitive tape from Scotch TM was applied over the coating using a rubber 
eraser on the end of a pencil. Adhesive tape was left for 90 seconds with a free end to simplify 
posterior removal. This tape was pulled by its free end in a quick manner at 180º. 
Another image is taken from the surface of the sample to compare the condition of the coating 
around the x cut area.  A rating was assigned to the quality of the coating based on visual inspection 
following the ASTM criteria shown next: 
• 5A No peeling or removal 
• 4A Trace peeling or removal along incisions or at their intersection 
• 3A Jagged removal along incisions up to 1.6 mm on either side 
• 2A Jagged removal along most of incisions up to 3.2 mm on either side 
• 1A Removal from most of the area of the X under the tape 
• 0A Removal beyond the area of the X 
• Each test is repeated three times to ensure repeatability. 
 
 
Design and production of multi-layered stents  
39 
 
Extraction and analysis setup for stents. 
 
Extraction of the different drugs found on stents was performed using 30 ml flasks. A stent is 
placed inside, and 5 ml of dichloromethane (DCM) are added to dissolve its coating (flask 1). The 
container is placed in an ultrasonic bath for 1 minute and the solvent is later separated in a different 
flask (flask 2). This process is repeated 2 more times, separating the solvent into the same flask (flask 
2) and storing the total of 15 ml. To avoid the hydrolyzation that may occur during the last step of 
evaporation, flask 2 is placed in an acetone bath cooled with dry ice. Next, liquid DCM (flask 2) is 
separated into another flask (flask 3) from ice remaining on the previous one. This ice remaining in 
flask 2 is broken down with a spatula and washed with 5 ml of DCM. Flask 2 is placed in the cool bath 
and liquid DCM is separated into flask 3. This process is repeated 2 more times rendering flask 3 with 
an approximate volume of 25 ml.  
At this moment, flask 3 contains the stent coating dissolved in DCM with no water. A current of 
N2 is used to completely dry the solvent without heating the container. When the container is almost 
dry, the liquid is passed to a smaller 3ml flask which is easier to store. Flask 3 is washed and sonicated 
with DCM 2 extra times to avoid losing any amount of drug in the process.  Evaporation with N2 is 
continued with the small container. Once this flask is dry, a cap is placed and sealed by wrapping the 
exterior with parafilm. From now on, the product is dry and sealed in N2, ready to be stored at 4ºC. 
All samples are refrigerated until they are analyzed through High-performance liquid 
chromatography (HPLC). Preparation of the samples starts with the addition of 0.25 ml of methanol. 
Next, they are sonicated for 1 minute and left in an orbital shaker at 100 rpms for 10 minutes to ensure 
dissolving the drug remains attached to the vial walls. The resulting solution is filtered before adding 
it to a micro-insert to avoid residues of insoluble polymers. 
HPLC 
 
The following HPLC system was used through all the work: ELITE LaChrom from Hitachi 
composed of the following modulus. Organizer, Diode array detector L-2455, column oven L-2300, 
autosampler L-2200 and pump L-2130. A Kromasil 100 C18 15x0,4 cm column with a particle size of 
5µm from Teknokroma was used to analyze the sirolimus releases. Samples obtained from the stents 
were extracted with DCM, dried and rediluted in 0.25 ml of methanol. To analyze the concentrated 
samples, micro-inserts were used in 1.5 ml vials (0.1 ml micro-inserts, 31 x 6mm, clear glass, 1st 
hydrolytic class, 15mm top). HPLC conditions were the following: Methanol as eluent, at a flow of 1 
ml/min. Oven temperature is set to 30ºC and the detection wavelength to 278nm.  
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Chromatograms are done up to a final time of 5 minutes per sample with a characteristic peak 
of sirolimus appearing at 2.3 min. A linearity check is done through a calibration line which has 
minimum and maximum values obtained from initial tests, plus a security margin. This calibration is 
seen in Figure 5, were a clear linear tendency can be seen in the working concentration range. 
Different methods were originally tried out which included different eluents, retention times, flows, 
temperatures and working volumes [45]–[49], but modifications were introduced until the quickest 
reliable way was found. Everolimus was also analyzed following the same process described with 
sirolimus, as the group had commercial stents which were also loaded with this drug. 
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Figure 5: Linearity curves for sirolimus and everolimus detection. Image at the left shows a calibration 
curve obtained with sirolimus samples prepared from 0.2 to 20 ppm. On the right, a calibration curve 
obtained with everolimus with samples that range from 0.2 to 100 ppm. Both graphs have been plotted as 
ppm vs peak area, showing their respective linear equation at the center.  
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2.3 Results and Discussion 
 
Setting up a characterization methodology 
 
In order to develop a new stent design, a validation process which allows the characterization 
of the coating was prepared. To fulfil this need, a methodology was set up by selecting the tests which 
rendered the most interesting data through the analysis of commercial stents. When characterizing 
stent coatings, an important data to search for is the amount of drug and polymer loaded on the stent. 
Various methods were proposed to quantify this. First, the stents were weighted with an analytical 
balance (Sartorius XS105 DualRange) to know their total mass and, right after, their coating was 
removed. The stent was weighted once more, so the difference in mass was equivalent to the weight 
of the coating. This process was performed on 4 different commercial stents as shown in Table 1. 
Separating polymer and drug from the strut was done by solvent extraction with the aid of an 
ultrasound treatment as described previously, presenting a solid and simple method which proved to 
work better than Soxhlet extractions.  
Table 1: Results obtained from a solvent extraction methodology used to quantify coating mass of different stents. Four 
different stents were weighed in order to obtain their coating mass. Dimensions of the stents are listed on the first column 
(exterior diameter x length). On the second column, the total mass in mg of each stent is shown. Strut mass is shown in the 
third column, which is obtained by weighing a stent after its coating has been removed. Weights obtained by the subtraction 
of the strut mass from the total mass are listed in the fourth column. This mass is equivalent to the coating mass. 
Stent dimensions / mm Total mass / mg Strut mass / mg Coating mass / mg 
4 x 18 33.185 32.625 0.560 
4 x 14 20.569 20.125 0.444 
2.5 x 18 22.484 21.919 0.565 
3 x 33 39.529 38.480 1.049 
 
Other 4 stents were analyzed by thermogravimetric analysis (TGA) in order to find out their drug 
load. These commercial stents were supplied with their composition data, so the results obtained 
could be easily compared with the ones provided by their suppliers. Results obtained are shown in 
Table 2, were the data presented shows that the drug load was about 51.8%, very similar to the 50% 
claimed by the supplier.  
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Table 2: Drug quantification obtained by TGA. Dimensions of the stents are listed on the first column (exterior diameter x 
length). On the second column, the total mass in mg of each stent is shown. The amount of polymer expressed as % is shown 
in the third column. Polymer mass obtained is listed in the fourth column. Results obtained are coherent with the ones 
provided by the suppliers. 
Stent dimensions / mm Coating mass / mg Polymer by TGA / % Polymer / mg 
4 x 18 0.560 48.571 0.272 
4 x 14 0.251 48.185 0.121 
2.5 x 18 0.444 48.198 0.214 
3 x 33 0.565 48.142 0.272 
 
 
Next, the composition of the polymer had to be fully detailed. To achieve this, several 
characterization techniques such as ToF-SIMS and HPLC were carried out on commercial stents. 
ToF-SIMS was initially selected, as it could be a useful method to determine the layer thickness of 
each coating. After several attempts, stent geometry presented complications which made this 
method unviable. If a stent is analyzed without modifying its geometry, no result is obtained, and if 
the stent strut is flattened, the coating cracks and peels off. In the end, initial results could only be 
used to characterize coating composition. As seen in Figure 6, characteristic peaks were found 
through ToF-SIMS which identified the polymer as PLA.  
 
 
Figure 6: ToF-SIMS obtained from commercial stent. Peaks obtained 
match the characteristic peaks found when analyzing PLA. This 
methodology can be used to check the polymeric nature of the coating. 
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These stents were also successfully characterized by HRMN as seen in Figure 7, showing 
valuable information. The coating was identified as PLA and the structure of the lactides were 
obtained. A characteristic shift at 5.1-5.3 ppm confirmed the mixture of D, L-lactide in these PLA 
coatings.  
 
 
Figure 7: HRMN obtained from a PLA coated stent. Image at the top shows the spectrum obtained 
from the coating. The image located at the middle shows an amplified area of the first spectrum, 
which is useful to identify the PLA structure. Images at the bottom display standard HRMN spectra 
used to identify lactide structures [50]. HRMN spectrum obtained is identified as poly (D,L-lactide). 
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 After obtaining the chemical composition and polymer/drug ratio of the coatings, it is important 
to analyze their morphology in detail. To accomplish this, the most effective way is to examine the 
stents with a SEM. Before surface examination takes place, various cuts and torsions were performed 
to separate the coating from the strut. This facilitated the obtention of coating thickness measures.  
When performing this surface aggression, coatings react in a similar way as when undergoing a 
balloon expansion. Images obtained can also offer a general idea of coating cohesion and adhesion 
to the stent strut. Figure 8 shows how after manipulating these stents, film thickness was measured, 
and the condition of the PLA coatings was checked.  
 
 
 
 
 
 
 
 
 
 
 
 
Once having a solid methodology tested, which enabled a good characterization of the coatings, 
the elaboration process of stents was initiated. Although new stent coatings could be designed at this 
point, a way to adhere the polymer to the strut should be optimized before continuing. Following, two 
of the most useful activation methods were tried out to find the most suitable one for our developing 
process. 
 
Figure 8: SEM images taken from commercial stents. On the first column, thickness is obtained 
by measuring the distance with the integrated software from the SEM. Images located at the 
second column show surface cracking with general good adhesion of the coating. 
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Surface treatments for optimal coating adhesion 
 
Surface activation is carried out in different ways to ensure a correct adhesion on the surface of 
the stents. Prior to a silanization process, the different methods described previously on “materials 
and methods” are tested on stainless steel samples. Surface modification was checked by contact 
angle as shown in Figure 9. Before silanization took place, surface treatments were applied to obtain 
modified surfaces presenting etching and the formation of hydroxyl groups associated to a reduction 
of the surface contact angle. Once silanization took place, as hydrophilic amine groups were going 
to be exposed, a reduction of the contact angle was also expected. Granting method “A” modified the 
contact angle much more when compared to others, methods which use acids are usually preferred. 
This is due to the stronger surface etching produced, which could increase the adhesion of the silane. 
Although method “G” produced a more hydrophilic result, this process was too aggressive and 
modified its surface in a manner which could affect its mechanical properties. A change in color due 
to heavy oxidation was seen in processes such as “F” and “G”. After seeing this data, method “D” 
was selected as optimal for the silanization process. Each sample was measured three times and 
triplicates were done for each process.  
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Figure 9: Contact angle on samples activated before and after silanization. Columns at the left of 
each method represent results pre-treatment. Columns at the right of each method show results post-
treatment. Contact angles under 90º on the left columns show surface modification through etching 
and hydroxyl formation. A low contact angle in the right columns indicates the formation of a silane 
coating. Untreated samples present a contact angle of 90º. 
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 Plasma activation was carried out as an alternative method for silanization. When testing 
plasma activation, an interesting idea found in scientific literature led to the addition of some extra 
experimentation. As seen in Choi’s et al research [51], the chemical bonds formed with PLA onto a 
substrate can induce a better adhesion with the surface while entangling with the next layer of polymer 
added. Continuing with this idea, plasma activation was done on three samples followed by soaking 
them in melted PLA. This was done without any solvents to assure the maximum amount of bonds 
forming between the substrate and the polymer. Samples were left to cool down at room temperature 
for 1 hour, and later on, the bulk was physically removed with a scalpel. What remains attached to 
the metal was slightly rinsed with acetone and air dried to remove polymer chains which had not 
bonded. Once dry, samples were stored 24 h, and after, contact angle was measured on each. A 
diagram of this process is described in Figure 10. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Illustrated process underwent to produce tangled polymer chains of PLA on a metal surface. Image “A” shows 
plasma activation done to prepare the surface before adding the polymer. Image “B” depicts how after activating and 
adding fused PLA, some polymer chains bonded to the surface. As seen in image “C”, the bulk of material was physically 
peeled, removing most of the polymer not bonded to the substrate. In image “D”, a slight rinse of acetone was used to 
take away the rest of polymer chains which were not bonded to the substrate located in the most interior layer next to the 
material surface. After this last step the material was air dried as seen in image “E”, right before the polymer was added 
again.  Last image, “F”, shows how after the polymer solution was added, the polymer chains were entangled with the 
already bonded ones. 
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Results achieved from plasma activation and from the entangled PLA chain experiments are 
presented in Figure 11. Method A showed a very low contact angle after plasma activation. This 
provided good wettability for the polymeric coating and the possibility of producing chemical bonding. 
Method B, C and D showed how, after their respective treatments, the contact angle matched the 
expected value derived from having a PLA coating. On the other hand, method D showed how results 
varied after removing the melted PLA from the plasma activated sample by physically peeling and 
rinsing with acetone. In this case, contact angles showed big variations depending on the analyzed 
area and samples due to the heterogeneity of the surface.  
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Figure 11: Contact angle on samples activated and treated with different coating methods. Starting from left to 
right, the first column shows contact angles obtained after the metallic samples were treated with plasma 
activation. Samples which had also undergone a plasma activation were dipped and their contact angle was later 
measured and presented in the second column. In the third column, samples had been treated with a plasma 
activation, coated with melted PLA, peeled, rinsed with acetone and then dipped. The fourth column shows samples 
which had undergone a silanization process and posteriorly dipped. In the last column, samples had been treated 
with plasma activation, coated with melted PLA, peeled and rinsed with acetone. Method A showed an excellent 
activation resulting in a very hydrophilic surface.  Method B, C and D showed contact angles corresponding to a 
PLA surface adhered to the substrate. These samples were ready to be used in an adhesion test. Method E showed 
a high dispersion due to certain areas which had been completely cleaned and no PLA was adhered. Each sample 
was measured three times and triplicates were done for each process. 
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If plasma activation showed good adhesion properties it could be a promising method due to its 
low industrialization cost. Four differently treated samples were coated with PLA and a scratch test 
was performed on each to evaluate adhesion. Each test was done in triplicate.  Figure 12 shows how 
these four different treatments modified the adhesion of a PLA film on stainless steel. A control group 
was tested by depositing a film of PLA on stainless-steel samples and reproducing the ASTM 
adhesion test (sample A). Films obtained in this test were reproduced by applying a dipping technique 
onto the metallic parts. Dipping was also applied to silanized (B) and plasma treated parts (C). One 
last sample was activated by a plasma treatment and coated with melted PLA. Then, the polymer 
was peeled, rinsed with acetone and dipped in a PLA solution (sample D). 24h later, the adhesion 
tests were performed.  
 
 
Figure 12: Adhesion test on differently activated surfaces. Samples are indexed with a letter in order to identify them and a 
number which clarifies if the image was taken prior reproducing the adhesion test (1) or right after finishing it (2). Images 
from the control samples are labeled as “A”. Label “B” depicts silanized samples while label C shows the plasma activated 
samples. Images labeled as “D” show the samples activated by plasma, coated with melted PLA, peeled, rinsed with acetone 
and dipped in a PLA solution. Label “E” shows samples treated as the ones labeled as “C”, but which had undergone a 
last flexing step in order to evaluate cracking. Controls show no adhesion and silanized samples show a 2A ASTM adhesion. 
In the other hand, the rest of samples show an excellent 5A ASTM adhesion result. Images were obtained by using a DM2500 
microscope from Leica. 
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In Figure 12, images labeled as “A” showed how a control was totally peeled off leaving the PLA 
film attached to the adhesive tape. These tests rendered a 0A adhesion in the ASTM adhesion scale. 
Images labeled as “B” showed a 2A adhesion result in which an entire section of the cross was 
removed as well as part of an adjacent portion. Images labeled as “C” showed the plasma treated 
and PLA coated samples which were rated as 5A. Labeled “C” and “D” images showed a 5A adhesion 
result. These last samples were also flexed, in order to see if cracks appeared, and the images 
obtained were labeled as “E”. These presented a good behavior and no surface defects were seen. 
Silanized parts presented better results than the control group, but were clearly not as good as the 
plasma activated samples. Seeing that plasma activations showed promising results, an adhesion 
test was carried out on samples activated with atmospheric plasma. As atmospheric plasma is easier 
to implement in an industrial environment, an analogous experiment was carried out with this method 
to check if the results rendered were similar. Images obtained from the scratch test done to each 
sample are presented on the next figure. 
Figure 13: Adhesion tests performed on surfaces treated with atmospherical plasma. Samples were indexed with a letter to 
identify them and assigned a number which clarified if the image was taken prior reproducing the adhesion test (1) or right 
after finishing it (2). Images labeled as “A” represented the control group which had a PLA solution deposited on top of 
the metal samples and were left to evaporate. Images labeled as “B” depict samples which had undergone the same 
experiment as “A”, but with a PLA solution twice as concentrated. “C” samples were submitted to the same experiment as 
“B”, but with a PLA solution twice as concentrated. “D”, “E” and “F” were treated as “A”, “B” and “C” with a single 
difference, they had previously been activated with atmospheric plasma. Worm-like and circular patterns appeared due to 
thick and high concentrated coatings. Samples with no activation treatment had the thick PLA layer removed. The rest of 
samples showed an excellent 5A adhesion. Images were obtained by using a DM2500 microscope from Leica. 
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Figure 13 presents the results obtained from the adhesion tests with atmospheric plasma treated 
samples. Images tagged as “A” show how portions from the upper right section were removed 
completely. “B” and “C” images show how samples lost a considerable amount of their PLA coating 
although the quantity deposited was so high that some polymer still remained in adjacent areas. 
Detailed exploration confirmed that images A, B and C showed a bad behavior when scratched even 
before the adhesion test was carried out. Images labeled as D, E and F showed a perfect result with 
a 5A adhesion behavior and no polymer removed. A granulated pattern could be seen on the samples 
as the PLA solution was added on top of the surfaces and dried afterwards, producing a thick and 
irregular layer. Atmospheric plasma was an interesting option to take in account due to its easy 
adaptation to an industrial process. Although this method also rendered good results, vacuum plasma 
was selected as the optimal method to activate stents. Due to its excellent results and disponibility in 
our lab, it was the most suitable activation method to achieve the objectives pursued. 
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Coatings elaborated with dipping techniques  
 
Traditional dipping was performed on stents through immersion in a PLA or a PLGA solution as 
described previously on the “materials and methods” section. This technique was useful and 
produced acceptable results, although webbing occurred randomly on some stents. Irregular coatings 
could also be an issue as they occur when these films break, leaving uncoated areas on the strut. 
During experimentation, this occasional phenomenon was documented as seen in Figure 14. 
 
   
 
 
 
 
A modified dipping protocol was applied to avoid surface defects and achieve better results. This 
technique was used to coat stents with PLGA and pHPMA as seen in Figure 15, guaranteeing 
smoother coatings. In these images no webbing or delaminations could be seen, although at some 
areas irregular morphologies were observed. While this may not be the optimal method used to obtain 
quality coatings, results proved to be acceptable to produce layered stents.  
 
 
Figure 14: Webbing and delamination phenomena registered from dipped stents. First row of 
images show webbing obtained in stents coated through a traditional dipping process. In the 
second row, an image displays delamination derived from physical removal of the PLA bulk 
caused by webbing. Images were obtained by using a DM2500 microscope from Leica. 
 
50 µm  50 µm  
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As the results obtained with both polymers were satisfactory, some experimentation was done 
to check if they could be produced in a multilayer structure. Three stents were coated with PLGA by 
modified dipping technique with different number of iterating dips. A first stent was dipped once and 
left to dry at room temperature (group 1). Two more stents were coated following the same procedure, 
but one was dipped three consecutive times (group 2) while the other one was dipped nine times 
(group 3). This experiment was done with triplicates and all stents were weighted before and after 
each dip was carried out, in order to evaluate the amount of polymer deposited.  Stents from the first 
group rendered a % of polymer/Strut (w/w) of 0.0823 ± 0.0294, the second group of 0.0905 ± 0.0272 
and the third group of 0.0346 ± 0.0203. 
These results indicated that the amount attached to the stents did not increase in a linear manner 
as desired. Although dipping times were short, this experiment was tried out once more with the 
shortest dipping times possible, but in the end, these rendered the same results. If a single layered 
coating was going to be tailored for a new stent design this technique could be useful, but it was not 
suitable for a multilayered proposal. With the purpose of validating our spraying technique to produce 
multilayered coatings, this same experiment was carried out once more by spraying stents instead of 
using a dipping method.  
Figure 15: Images from a stent coated with a modified dipping method obtained by using a DM2500 
microscope from Leica. First row of images displays pHPMA coated stents while the second row 
shows PLGA coated stents. No webbing or delaminations were observed in these stents.  
Design and production of multi-layered stents 
53 
Coatings elaborated with a laboratory sprayer 
As the ability to stack layers was key to achieve correct multilayered coatings, a similar 
experiment as the one described with dipping was performed with sprayed stents. Three stents were 
sprayed a different number of layers and weighted before and after the process was completed to 
quantify the amount of polymer deposited on each.  Not all parameters were optimized in this first 
experiment, as this only evaluated the capability of stacking layers without considering surface quality. 
 Results obtained from these tests are shown on Figure 16, comparing them with the dipping 
results obtained previously. As depicted before, dipping methods show how the quantity deposited 
after one or three consecutive dips were very similar. After nine consecutive dips, the quantity of 
polymer on the stent reduced drastically. This reduction was associated to the dissolution of previous 
coats in the dipping mixture. As the layers were not fixed in any manner which protected the polymer 
from the solvent, further dips did not contribute to an increase in coating thickness. Three other stents 
were sprayed two, four and eight times to build different layer thicknesses. These stents were 
weighted before and after the process was finished. Each condition was tested in triplicate with 
different stents. 
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Figure 16: Spray vs dip methodology for multilayers coatings. Triplicates of each 
type of stent are shown with different number of layers pursued by spraying or 
dipping. Labels in the x axis show the coating technique applied followed by the 
number of repetitions/layers. Spraying technique showed accumulative results (first 
three columns) which validated this procedure as adequate to produce multilayered 
stents. The last three columns (dipping) displayed non accumulative results due to 
the dissolution of previous coats in the dipping mixture, thus not presenting 
satisfactory results for multilayered coatings. 
Chapter II  
54 
 
This spraying technique proved to be a reproducible and repeatable method to elaborate 
different thickness layered coatings. In this case, the modified dipping method did not offer this 
possibility while working with the selected polymers. Considering these outcomes, a spraying method 
was chosen to achieve the multilayered coatings pursued. As described in the materials and methods 
section, to obtain quality coatings through spraying all parameters had to be optimized. These 
parameters were fixed as different stents were sprayed and checked through a DM2500 microscope 
from Leica. A first optimization was done using pHPMA with mixes prepared at 0.2% w/v. 
To evaluate the quality of the layers, 50 mg of fluorescein were added to the 10 ml of spraying 
solution to check the uniformity of the layer. Images obtained by this system provided a better 
visualization of the coating homogeneity. A stent was sprayed with five layers of this mixture and 
checked on an optical fluorescent microscope (Nikon eclipse TE 2000-U) as seen in Figure 17.  This 
image provides a general idea of the layer’s morphology in which no patches or large uncoated areas 
are seen, thus encouraging a deeper inspection by SEM. 
 
 
 
 
 
Figure 17: PLGA sprayed stent with fluorescein. At the left, a brightfield image of the stent is displayed. At 
the right, its corresponding darkfield image was obtained to check for fluorescence corresponding to the 
presence of a polymer layer. This images show a homogeneous coating with no patches or large uncoated 
areas. Images were obtained with a Nikon eclipse TE 2000-U microscope. 
 
 
Stents were sprayed with ten pHPMA layers right after undergoing a plasma activation. SEM 
images were taken to check surface morphology, as seen in Figure 18, showing a very smooth and 
homogeneous coating. Spraying conditions fixed at this moment rendered quality layers with pHPMA 
and were suitable for multi-layered configurations. As this method produced quality pHPMA coatings, 
the same method was replicated with PLA and PLGA. In Figure 19, experimentation was repeated 
with PLA, but results showed poor-quality coatings in the form of small drops scattered through the 
strut. Willing to maintain a low concentration spraying mix to keep the layers as thin as possible, the 
concentration was raised until acceptable results were obtained.  
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Figure 19: Ten PLA layered stent sprayed at 0.2% w/v. Images labeled A-D show bad quality coatings 
obtained with PLA, further optimization had to be done. EDX spectra obtained from the areas surrounding 
the drop-like structures (D1 and B2) showed absence of C peak. On the other hand, B1 and D2 showed a 
clear C peak due to the polymeric coating. EDX was useful to validate the presence of PLA in the drop-like 
structures and to prove PLA absence in the rest of the strut. 
Figure 18: Ten layered pHPMA stent sprayed at 0.2% w/v. In the SEM image shown at the left, a smooth 
pHPMA coating obtained by a spraying technique can be observed. At the right, an EDX spectrum 
confirms the presence of pHPMA through a C peak. 
C 
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Mixes prepared with a 1% w/v showed better results with pHPMA, PLA and PLGA.  PHPMA 
layers exhibited smooth morphologies, independently of the mixing concentration variations at these 
low ratios.  Figure 20 depicts struts sprayed with different number of pHPMA layers with a 1% w/v 
mixture. Quality of these coatings was excellent for multi-layered applications. Determination of 
polymer presence at the surface of the strut was checked through EDX analysis. A quick verification 
test was also prepared to visually assure that the smooth coating observed was pHPMA. Activation 
and pHPMA spraying processes were repeated with stents which had been partially masked with 
PTFE tape. As seen in Figure 21, a clear interphase is observed through SEM imaging after removing 
the tape, separating the coated area from the metallic uncoated surface and providing a fast visual 
confirmation of the polymeric layer. 
 
Figure 20: SEM images of optimized pHPMA coatings sprayed on activated stent struts. Images at the left column illustrated 
five layered coatings obtained after spraying with pHPMA. On the middle column, images presented ten pHPMA layered 
stents. Images at the right column showed a thick and smooth pHPMA coating composed of twenty layers. Samples had 
been sprayed with a 1% w/v mixture rendering smooth coatings with five, ten and twenty layers. 
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PLA coatings obtained with these same spraying conditions exhibited more homogeneous 
coatings. Although results obtained with PLA showed stent struts completely coated, these were not 
perfect. The whole stent struts revealed PLA presence through EDX analysis, but some sections 
show occasional reduced thicknesses with well-like structures. This micro-phenomenon was 
observed at random spots and its reduction was associated with an increase in the number of layers. 
Results are detailed next in Figure 22. 
Figure 21: SEM images obtained from pHPMA coated stents with an uncoated interphase. Images at the left column 
showed a five layered stent interphase. At the middle column, images displayed were obtained from a ten layered stent. 
The image at the right was acquired from a twenty layered stent. Images showed interfaces separating the polymeric 
coating from the masked metallic strut. This test was used as a quick presence verification for polymeric coating. 
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Figure 22: SEM images of optimized PLA coatings sprayed on activated stent struts. Images at the left 
column (A, B and C) showed five layered PLA coatings sprayed with 1% w/v mixtures. At the right 
column, images (D, E and F) showed results obtained after applying ten layers of PLA. A reduction of 
this well-like structures was observed as the number of PLA layers increased. 
 
This process was tried one last time with PLGA to check the morphology obtained, rendering 
the excellent results shown on Figure 23. At this point, all conditions were optimized to achieve quality 
coatings on struts by a lab scale spraying technique applied after plasma activation. A next step to 
focus on was to achieve mixed multi-layered stents with these polymers. 
 
 
 
 
 
 
 
 
Figure 23: SEM imaging and EDX analysis of ten layered PLGA coated stents sprayed with 
a 1% w/v mixture. Coating were confirmed by the presence of a C peak at EDX spectrum. 
Homogeneous smooth results were obtained with PLGA coatings. 
Design and production of multi-layered stents  
59 
 
Design of first pHPMA/PLGA multi-layered stents 
 
Data obtained up to this point was used to design a first model for a multi-layered stent. This 
basic prototype was going to be composed of different layers of pHPMA and PLGA/PLA to achieve 
controlled pharmacological liberation. Activation of the metallic strut was performed through vacuum 
plasma with an O2/Ar flow and the coating was sprayed on top with a 1 % w/v concentration. Target 
drug loads of 50% were achieved using sirolimus, a golden standard in the market. A metallic comb-
like structure was used to place up to four stents in the plasma reactor to activate their surface 
simultaneously. Once the activation process was completed, these struts were removed from the 
reactor to undergo an immediate spray coating process.  
A first stent design was proposed, which had a thick interior core composed of pHPMA in contact 
with the stent strut. This initial pharmacological reservoir was elaborated by the addition of eighteen 
pHPMA layers over the stent strut right after the activation process was completed.  As mentioned 
before, this polymer had already been used in our group and tested in-vivo, showing an excellent 
behavior when placed in contact with live tissue. As the drug release obtained from a pHPMA matrix 
could be excessively fast, a second layer of PLGA/PLA placed on top of the pHPMA coating was 
thought to help reduce this liberation. PLGA or PLA could reduce this release with only a few layers 
so, having in mind previous discussed recommendations (minimum of two-three layers to have a solid 
coating), a minimum of three layers was fixed. To assure this, three stents were sprayed with this 
combination of polymers. Complete coatings were obtained through eighteen layers of pHPMA (first 
coating) and three layers of PLGA/PLA (second coating). As a last third coating, a thin pHPMA film 
was placed on top to enhance adhesion with the artery wall in future designs. This was thought to be 
sufficient with the same three layers as with the PLGA/PLA coatings. 
The testing of this initial design was used to clarify if the multi-layered elaboration idea with 
different polymers such as pHPMA, PLA and PLGA was functional with the set up developed at this 
laboratory. Execution of this idea was carried out starting from the plasma activation of three stents. 
Immediate after, they are sprayed to create the first pHPMA layers. A small fan was placed close to 
the stents to generate a light air current which enabled a thorough drying of the spraying mix. 
Completion of this process was assumed after two minutes, and it was repeated after ending each 
coating. Finished stents were analyzed through SEM imaging to check their morphology. Some 
examples are shown in Figure 24. 
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The stent shown on the previous figure presented a mix of the morphology seen previously with 
PLGA coatings and pHPMA throughout the surface. Image displayed in Figure 24 showed a 
difference in coloring attributed to a change in thickness. To assure a more homogeneous result, 
configurations elaborated with five to eighteen layers are recommended in order to render the same 
smooth layers obtained previously. Now that stents sprayed with this methodology and 
instrumentation showed adequate morphologies and tailored distributions, new designs could be 
pharmacologically loaded and studied as seen throughout the next chapter. 
Figure 24: Composition and SEM imaging of first multi-layered stent design. At the top part, SEM images displayed the 
morphology of a multi-layered stent composed of eighteen layers of pHPMA, three layers of PLGA and three layers of 
pHPMA. These SEM images showed an expected morphology for the selected layer distribution. A characteristic 
morphology was displayed, showing a mix of both polymers slightly smoothed by the last layer of pHPMA. The Image 
located at the bottom showed a sketch clarifying the polymer layer distribution for the stents elaborated in this last section 
of the chapter.  
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2.4 Concluding Remarks 
 
This chapter presents an in-lab procedure to analyze, characterize and elaborate multi-layered 
stents. A deeper knowledge obtained by studying the composition of various market golden standards 
has proven useful to design coherent polymer coatings to use on next chapters with reasonable drug 
loadings. Viability of silanization and various types of plasma activation techniques have been tested 
for stent use, being vacuum plasma, the method selected as optimal for our laboratory. Adhesion of 
the polymers to the metallic surface was validated through ASTM scratch test with excellent results 
for samples activated through plasma processes. Dipping and spraying methodologies have been 
used to elaborate stent coatings, creating variations for traditional dipping techniques to obtain better 
quality results. Both systems, dipping and spraying, proved useful to obtain polymeric coatings on 
stent struts, although only spraying was adequate for the obtention of more than one layer on a same 
stent.  
A first multi-layer design has been proposed and elaborated using the apparels and methods 
designed for this purpose as described through the chapter. Stents obtained have shown excellent 
quality coatings which enable the study of controlled release with different variations on polymer and 
drug combinations. On the next chapter, new designs will be tested with different pharmacological 
contents to achieve a novel stent which performs as desired.  
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3.1 Introduction 
During this third chapter, a variety of DES designs are going to be studied through their drug 
release. Results obtained guide the research in order to learn how different ways of elaborating multi-
layered coatings affect the pharmacological liberation. Through this process a complete control of the 
release is sought, enabling the elaboration of tailored coatings which can liberate pharmacological 
treatment at a desired rate and time. At the end of this chapter, a new DES prepared for in-vivo testing 
is produced. To start the chapter, a brief introduction sets the importance of antiproliferative drugs in 
DES.  Through this section, basic concepts such as how is the drug released to the injured area or 
how is their effect tested, are explained. Following, an experimental section will be focused in the 
obtention and analysis of release profiles. This process will be accumulative, meaning that each 
experiment adds knowledge on how to control drug release in specific situations and influences the 
next designs tested. As mentioned, this will add up to enable a DES design which will bring best 
results with the polymers and drugs used. Following, a brief introduction focused on the effect of 
antiproliferative drugs and polymers used for stent coatings will present this chapter and will identify 
the main issues which will be encountered when developing novel DES designs. 
As described in previous chapters, 2nd-generation DES have dramatically improved the safety 
and efficacy of PCI [1]–[3].  In the Limus family, everolimus eluting stents (EES) have demonstrated 
their superiority when compared to bare metal stents and 1st-generation DES, in terms of rates of 
target lesion revascularization and stent thrombosis [4][5]. These stents have been the bench mark 
for emerging DES for several years and even though many competitors have emerged on the market, 
new DES are mostly equivalent to EES except for the carrier matrix [6][7]. A clear tendency to reduce 
the size of the stent strut has also been observed as this reduces the inflammatory response. This 
progression can be seen through different stent generations in Figure 1. 
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Figure 1:  Progression of strut thickness through generations. From left to right, 
thickness and material changes performed to the stent struts in order to reduce 
inflammatory response during stent implantation. Adapted from [8]. 
 
 
 Although drugs used in DES are mostly from the Limus family, except for paclitaxel, the search 
for new antiproliferative drugs is not over. This is due to the need of finding a solution for delayed 
healing of the stented lesion [9]. Antiproliferative drugs inhibit proliferation of endothelial cells, as well 
as smooth muscle cells, being of vital importance to achieve a controlled release which is reduced at 
the final stages of DES liberation.   
To search for a suitable and innovative drug for DES, this must be capable of inhibiting the well-
known cascade of restenosis, including platelet aggregation, inflammation, smooth muscle cell 
proliferation and migration, as well as extracellular matrix formation [10]. As to promote appropriate 
healing these drugs should have a selective mode of action, several drugs should be used, treatment 
should be complemented with anti-platelet therapy or the amount of drug released should be 
controlled. This last strategy needs a mix of varied polymers or the careful tailoring of different burst 
layers and barrier layers to be successful. Burst layers, as treated in this work, are designed as quick 
drug eluting coatings which are used to inhibit SMC proliferation at early stages, and which should 
not be used at final phases. On the other hand, barrier layers are used to slow down drug release at 
a given stage or to avoid external layers to lose pharmacological load during stent deploy. 
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Apart from the Limus drug family and paclitaxel, other drugs could be used to fulfil their task in 
a more fitting way. An example of this is 5-(4-phenylbutoxy) psoralen (PAP-1), an antiproliferative 
drug which acts blocking the voltage-dependent Kv1.3 channel. Up to date, a decrease of ion 
channels expression on proliferative switch is observed, except for Kv1.3 channel and Kv1.2 auxiliary 
subunit. As the Kv1.3 increases, the dominant channel in the contractile state, Kv1.5, decreases. The 
importance of Kv1.3 channel is recognized because its functional expression is associated with the 
proliferative phenotype. This is supported by the fact that channel blocking induces a significant 
inhibition of cell proliferation. The relevant role of Kv1.3 channels in VSMC proliferation has also been 
shown in a human model of neointimal hyperplasia, which supports previous statements [11]. 
Furthermore, association between Kv1.3 expression and cell proliferation has been studied in many 
cell types such as several cancer lines [12][13], endothelial cells [14], lymphocytes [15] and 
macrophages [16] among others. Apart from its interesting properties, PAP-1 has been used in our 
group with positive in-vivo results by deploying it in a pHPMA matrix, making this drug a good option 
for DES [17]. Due to these results, pHPMA is one of the polymers selected to produce tailored 
coatings. During this chapter, initial release screenings are performed using sirolimus due to the high 
difference in cost compared with PAP-1. 
Bioresorbable stents depend much on the polymers used as they are the ones which will mostly 
affect the drug release and the inflammatory response caused during a stent implantation. Some of 
the most commonly used in order to fulfil this duty are Poly-L-lactic acid (PLLA), poly-D,L-lactic acid 
(PLA), poly-caprolactone (PCL) and polyglycolic acid (PGA), aliphatic polyesters and different blends 
of these [18][19]. PLLA and poly-D-lactic acid (PDLA) have a high tensile strength which permits 
robust designs but, at the same time, exhibit long degradation times. On the other hand, PGA and 
PCL show less tensile strength but much faster degradation times. 
 As mentioned before, combinations and blends of these different polymers help achieve 
controlled releases with their diverse degradation rates. This phenomenon is mostly dominated by 
simple hydrolysis of the ester bond in the polymer backbone, and although it is not the only parameter 
affecting it, it is considered the predominant one. When partial chain scission occurs, the polymer 
breaks down to 10-40 μm sized particles which are then phagocytosed and metabolized into carbon 
dioxide and water in order to be resorbed [20]. 
Degradation rates are highly influenced by the chemical structure of polymers and their 
molecular weights. A practical example of this can be seen with PGA, which typically degrades over 
a time period of 6-12 months while PLLA takes over months to years. Table 1 shows degradation 
rates of common polymers used to create stent coatings [21]–[35] . 
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Having seen the variety in degradation rates obtained with different polymers, the next key factor 
to have in mind is the inflammatory response caused by these. Inflammation has not been observed 
in an aggressive manner as a result provided by the use of the polymers previously mentioned, but it 
is something that must be studied in new polymers assigned for drug release purposes [36]. In 
Chapter I, the importance of the inflammatory response due to polymeric coatings has been 
discussed and therefore its relevance is understood.  
As discussed previously, VSMC proliferation is one of the most important indicators of restenosis 
after stent implantation in animal models as well as in humans. This observation has attracted 
researcher’s interest along the years and has rendered numerous articles about molecular 
mechanisms which control the cell cycle during in-vivo and in-vitro experiments. In addition, preclinical 
studies have also contributed to clarify the effectiveness of antiproliferative strategies in order to limit 
neointimal development during a lesion when applying gene therapy and drug release treatments.  
 
 
 
 
Table 1: Properties of biodegradable polymers used for drug elution. This table shows molar mass, tensile strength, glass 
transition temperature, tensile or flexural modulus and degradation times of different biodegradable polymers. Information 
provided in this table can be particularly useful as a quick reference for pharmacological elution times depending on the 
carrier matrix. Adapted from [51]. 
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This chapter is focused on the development of new coating designs based on drug release 
strategies which are going to be tested in animal models to limit neointimal lesion development. 
Before undergoing in-vivo testing with humans, animal models are a key factor to achieve a better 
understanding of the mechanical model of neointimal thickening produced after stent implantation or 
balloon angioplasty, to establish safety margins and to have some initial results related with efficacy 
and toxicity [37]–[39]. 
When planning an in-vivo on animal models, rats have been extensively studied specially for 
balloon angioplasty. Nevertheless, prior to a human in-vivo, porcine and rabbit models are nowadays 
considered standard for the evaluation of drug eluting stents  [37]–[43] . Although animal in-vivo trials 
are useful and contribute with significant data, there are known differences on results obtained from 
animal trials when compared to human. These known variations limit their biological significance. 
Furthermore, drug eluting stent are usually implanted on atherosclerosis-free vessels when tested on 
animals, showing a cleaner scenario with a quicker recovery than expected. Additionally, neointimal 
response caused by stent implantation is exaggerated in pigs and rabbits, and the healing time is 
reduced (4-6 weeks in pigs and rabbits and 6-9 months in humans).  
Rabbit models show an additional particularity as they do not offer the possibility of coronary 
stenting due to their small size, being the aorta or the iliac arteries the most suitable stenting locations 
for this purpose. Although this might seem a great drawback when using rabbits for this type of 
practices, its healing process is closer to humans than to pigs and therefore it’s also widely used to 
study inflammatory, proliferative and thrombotic reactions [39]. 
Some main issues have already been presented such as: Which in-vivo should be used to test 
these new stents? Which polymer combinations should be targeted in this Chapter? How many layers 
should be targeted for final designs? Which drugs should be tested for initial designs? All these are 
main issues tackled in this chapter. As the previous work has constructed the bases which enable 
the production of different multilayered stents, Chapter III will be centered on achieving tailored drug 
release and producing novel stent designs. As described in Chapter I, the goal of this chapter is to 
achieve complete control of drug release in order to produce a target type of stent which will be 
designed to perform with a designed release profile. This stent will be tested in an in-vivo trial to check 
its efficacy. 
 
 
 
Chapter III 
74 
3.2 Materials and methods 
In-vitro drug release 
HPLC system, extraction methodology and chromatogram configuration were used as described 
in chapter II for sirolimus analysis. On the other hand, PAP-1 was also used to pharmacologically 
load stents in this chapter. This drug was treated the same way as sirolimus when extracting and 
preparing it for the analytical process.  Several methods were initially tried out to analyze PAP-1 
content through HPLC [44]–[47], but in the end, the one which rendered best results was the same 
modified method used for sirolimus. Calibration curves were done in the working range to check 
linearity for PAP-1, enabling drug quantification. 
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Figure 2: Calibration curve of PAP-1 elaborated with samples ranging from 0.2 to 50 ppm. A trend line with its associated 
equation and quadratic error is shown on the graph. These graphs were elaborated before a release analysis was performed 
in order to have a quantification method available. 
As done in the previous chapter with sirolimus, PAP-1 spraying mixes had to be optimized by 
preparing different solutions and checking the coating quality obtained through SEM imaging. This 
drug was sprayed in acetone when mixing it with PLA or PLGA, but the solution varied when using 
pHPMA. This last polymer is soluble in ethanol, but PAP-1 shows a very low solubility in this solvent. 
To create the spraying mix, a proportion of 33% of ethanol with 66% of acetone showed best results. 
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Spraying in an industrial environment 
 
Throughout this chapter, practically all stents were sprayed with the same machine elaborated 
during chapter II. Only the last type of stent, shown at the last part of this chapter, is prepared on an 
industrial spraying machine provided by Iberhospitex SA. This change was proposed to try the 
scalability of the process and to obtain the best quality results possible. An image showing this 
industrial sprayer can be seen next in Figure 3. Basic parameters had to be optimized in order to 
obtain repeatable results. Pump flow for example, was slowly increased until a steady and constant 
solvent spraying cone was obtained. In the case of PLGA mixes, the flow was finally set to 0.035 
ml/min while pHPMA mixes were set to 0.08 ml/min. 
 
 
 
 
 
 
 
 
 
Figure 3: Stent sprayer provided by Iberhospitex SA. At the center of the image a sonicating 
tip and a spraying mix output are shown. At the bottom part, two metallic cones were used 
to hold and rotate the stent strut throughout the spraying process. While the cones spin and 
rotate the stent strut, the sprayer moves horizontally over the stent from left to right and 
later, from right to left completing a whole cycle. 
 
Another modification had to be done to the solvent composition of the mixes to achieve a 
constant flow in the industrial sprayer due to the volatility of the solvents. PLGA was dissolved in 
dioxane instead of acetone, while pHPMA required a mix of 20% ethanol and 80% dioxane instead 
of only using ethanol. Air pressure was set to 0.95-1 bar for all spraying mixes used with this machine 
and finally, calibration curves were done with polymers which were going to be used to check linearity 
in the working range. This was useful to ascertain how many times the nozzle had to pass over the 
stent to achieve a desired quantity of polymer on the strut.  
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On the case of PLGA mixes, a correct nozzle speed was found to be 230 mm/s, while pHPMA 
was set to 300 mm/s. This speed was fixed after checking the mass increase deposited on the strut 
after each iteration. If the mass added was constant and similar to the one obtained with the lab 
sprayer, the speed was acceptable. Results were checked through SEM imaging to validate the 
coating quality. Calibration curves obtained with both polymers at the working range are seen in 
Figure 4. After adjusting all parameters, these graphs verified that the number of layers sprayed on 
the struts increased lineally with the number of times the sprayer’s nozzle passed over the strut. When 
the mixes are prepared with a 50/50 polymer/drug weight ratio, the weight of the coatings include 
polymer and drug. When preparing stents for in-vivo testing, the struts are charged with 153.1 +- 0.8 
µg of PAP-1. 
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Figure 4: Calibration of industrial sprayer with PLGA 50/50 (left) and pHPMA (right). Both show linear 
results which are suitable to validate a given set of parameters as capable of producing repeatable results. 
Stent struts were sprayed a given number of layers and then weighted. The same strut underwent the process 
again to accumulate a different number of layers and its weight was checked again. This process was 
repeated until verification lines were complete. 
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In vitro evaluation through scratch test in pharmacological liberation medium 
 
Stents designed in this chapter which presented an interesting pharmacological liberation were 
studied in an in-vitro scratch test. To achieve this, a modified version of the scratch wound essay 
[48]–[50] was done in order to have information on the toxicity of stent liberations or effectiveness of 
the pharmacological load present in the medium. Throughout this experimentation, a cos-7 cell line 
was used to obtain a quick and easy procedure which would be useful as a check test to control the 
effect of drug concentration released into the medium. To prepare this experiment, cells were seeded 
in 12 well plates (0.3 x 106 cells per well) and incubated in supplemented Dulbecco’s modified Eagle’s 
medium until a cell monolayer was achieved. Next, a wound was scratched at the center of the well 
using a 200 µl pipette tip in a flowing movement to give a clean straight edge. Each well was washed 
with PBS to remove scratched cells. Control wells were then treated with normal growth medium while 
the rest were treated with medium which contained PAP-1, as these other wells corresponded to 
different elution time points obtained from pharmacologically loaded stents. 
Bright field images were acquired from each well after producing a scratch at the initial time point 
and next, images were obtained at the same spots 28 hours later. Wound closure was evaluated by 
calculating the area repopulated by cells using a cell tracking software (ImageJ, free to download 
from https://imagej.nih.gov/ij/download.html). Later, images from time points t=0 and t=28h were 
paired and used to evaluate the percentage area closed of each wound. 
 
Porcine Model of Coronary in-Stent-Restenosis for in-vivo trial. 
Thirteen Large-White x Landrace pigs (30.2±1.7 kg) underwent a percutaneous coronary 
intervention to stent each one of the main coronary arteries. Twenty-four hours before coronary 
catheterization, animals received loading dose of aspirin (200 mg) and clopidogrel (300 mg) (PO). 
Fasting animals were anesthetized and ventilated. Under aseptic conditions, a 6 Fr introducer was 
percutaneously placed into the femoral artery for coronary access. During the procedure, an 
appropriate anticoagulant treatment was maintained with an initial bolus of 9000 UI of heparin 
followed by boluses of 1500 UI of heparin every 30 min, if needed, in order to maintain an adequate 
anticoagulation range.  
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Using standard over-the-wire techniques, the three main coronary arteries were engaged with a 
5-Fr guiding catheter. Radiopaque contrast (Iomeprol 350 mg/ml, Iomeron 350, Bracco, Wycombe, 
UK) was administered to obtain coronary angiographies, which were used to screen for appropriate 
vessel segments for stent implantation on the basis of anatomy and the diameter (between 2.3 and 
3.0 mm) measured in situ on a fluoroscope console (Arcadis Avantic, Siemens AG, Germany). 
Polymer-coated, with or without PAP-1, stents of 3 mm in diameter and 23 mm of length were then 
implanted in the selected coronary segments. For stent deployment, angiographic contrast was used 
to inflate balloon at 7 to 15 atmospheres (2.97-3.37 mm) for 10 seconds to achieve a stent-to-artery 
ratio (SAR) of 1.1-1.3.  
Only stents with the same treatment (with or without PAP-1) were implanted in each animal 
(control group, n=6; PAP-1 group, n=7) and only coronary arteries with a diameter suitable for the 
aimed SAR were stented. Two left anterior descending coronary arteries from PAP-1 animals resulted 
too small for the desired SAR. Thus, one more animal was included in the PAP-1 group, in which the 
left anterior descending and circumflex coronary arteries were stented. After angiographic 
confirmation of correct stent deployment, animals were awakened and weaned from mechanical 
ventilation. Dual anti-platelet therapy was continued with 200 mg aspirin and 75 mg clopidogrel daily 
during the 28 days follow-up. 
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3.3 Results and Discussion 
 
 
3.3.1 Analyzing elution of different polymers in quick release medium 
 
 
Following the design and fabrication procedures described in the previous chapter, some 
polymers were selected with the intention of elaborating coatings for DES and acquiring more 
information about their release profiles. To achieve this, three interesting DES designs were 
elaborated and left in an accelerated medium to be subsequently analyzed by HPLC. These stent 
coatings were composed of five layers of PLA, PLGA, or pHPMA with a 2% drug load of sirolimus 
each. A small drug load was added with the intention of limiting its possible effect on the general 
release as well as to reduce the amount of drug used during the first experiments. Another factor 
which also modified initial liberations was the use of accelerated medium. During the liberation 
process on an accelerated medium the small percentage of isopropanol mixed in the saline medium 
increased the drug release over time, but most important, it also reduced the degradation of sirolimus 
present on the medium. As releases were obtained faster, liberation curves had to be compared to 
others obtained using the same medium, but most important, this led to a reduced degradation which 
enabled the obtention of the most accurate HPLC results possible.  
When the release profiles were obtained, they were plotted as seen in Figure 5. This graph 
showed a slow liberation curve which reached an 80% elution after one hundred and seventy hours 
from a five PLA layered stent in accelerated medium. In the other hand, over this curve, a liberation 
from a blend composed of 50% glycolic acid showed a coherent quicker release which pushed the 
elution curve upwards in the graph. Finally, over the PLGA curve, a pHPMA matrix liberation showed 
an extremely fast elution when compared with the other two polymers, achieving an 80% release 
during the first hour. All three different stents were elaborated by triplicate with the purpose of having 
information about the repeatability of the fabrication methods developed for this purpose.  
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Figure 5: Sirolimus release from DES composed of five layers of different polymeric matrices charged with a 2% drug load 
in an accelerated medium. Total release was plotted as % released from the strut vs time (h). A slow elution was obtained 
with a PLA matrix, an intermediate release was achieved with a PLGA matrix and a fast release was observed from a 
pHPMA matrix.  
 
 
After obtaining this data, the release achieved by the coatings made of PLGA, PLA and pHPMA 
were repeatable and showed promising results in order to start designing multilayered stents with 
different elution profiles. The quick elution obtained from a pHPMA matrix led to the idea of using this 
polymer to create a burst effect in a multilayered stent at a desired time point. This could be used to 
have a better control of the drug elution in a DES, but before creating specifically tailored layers 
successfully, a better understanding of the effect of drug and polymer concentrations had to be 
achieved. 
 
3.3.2 Study of the effect of drug and polymer concentrations on 
pharmacological elution through release analysis in quick release medium 
 
Driven by the need to acquire more information on the influence of the hydrophobic drug 
concentration and the thickness of the polymer layer, three different multilayered stent designs were 
prepared. These three types of stents were composed of ten, twenty and thirty layers of pHPMA 
charged with a 20% of sirolimus. This increase in drug load, compared with the previous stents 
discussed in Figure 5, was due to the idea of using higher drug loads which would resemble more 
the actual market standards.  These stents were left in accelerated medium for one week and the 
results obtained were graphed as seen in Figure 6.  
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During this first timepoint, a reduction of drug release was appreciated when the amount of 
polymer was increased. As the concentration of sirolimus was constant throughout all the layers, 
results showed that outer layers eluted quicker than interior ones (which were attached directly to the 
stent strut). As the pHPMA layers eluted very fast, thicker coatings also showed that the bigger outer 
layers which dissolve in the medium also drag bigger quantities of the inner layers. Smaller coatings 
had thinner layers which eluted in a less turbulent way. After obtaining this information about pHPMA 
layers, burst coatings could start to be designed for DES in a coherent way and could be used to 
boost an initial release after implantation. 
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Figure 6: Sirolimus release of thirty, twenty and ten pHPMA layered stents with 20% drug load in an 
accelerated medium. Total release was plotted as % released from the strut vs time (h). This graph shows 
three different behaviors during the first 100 hours and provides a zoomed highlight of the first hour to 
check the initial tendencies. Quick releases were observed from pHPMA matrices which had a more 
controlled liberation with a higher drug load (20% instead of the previous 2%). Dragging effects are 
observed at thirty-hour time points which suggested keeping the layer amount of pHPMA not much higher 
than twenty. An increase in the layer thickness also showed a reduction in the initial liberation.  
 
 
This dragging effect previously seen with thick layers of pHPMA can be a problem if the objective 
is to design thick layers of this polymer to use as a carrier matrix. To solve this issue, a new design 
was conceived which consisted in the addition of a small pHPMA coating on top of a stable and slower 
eluting polymer while also keeping pHPMA layers under twenty. To accomplish this, two different 
types of DES were developed. One had an interior coating of eighteen layers of pHPMA, three layers 
of PLGA on top and three exterior layers of pHPMA. All these layers contained a 20% drug charge 
which would be eluted on the medium. The other type of stent was elaborated the same way but with 
a thinner coating of eight layers of pHPMA in its interior. Both stents were provided with three final 
outer layers of pHPMA, as this polymer had proven in previous studies a good adhesion to the artery 
wall and could also provide a good grip in future designs during implantation.  
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As the previous release points obtained in accelerated medium indicated that most of the 
pHPMA was eluted during the first hour, the next experiment provided five elution points during the 
first sixty minutes. Results obtained were plotted as seen on Figure 7, which showed a combined and 
modulated release of PLGA and pHPMA layers avoiding the violent dragging phenomenon. In 
addition, the layer thickness phenomenon described previously and seen in Figure 6, is also seen in 
Figure 7. 
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Figure 7: Sirolimus release in accelerated medium of different pHPMA and PLGA layered stents with 
20% drug load for one hour. Total release was plotted as % released from the strut vs time (min). This 
graph shows two detailed release curves during an initial liberation period of one hour. PLGA 
intermediate coatings were applied to modulate liberation, resulting in a general reduction which 
evidences concentration phenomena. No dragging effects were observed. 
 
Now that the influence of the polymer layer thickness had been studied, the impact of the drug 
load in the polymer matrix had to be tested. Aiming to obtain more information on this matter two 
more types of stents were elaborated, and their elution subsequently analyzed. Following the 
multilayered composition of eighteen layers of pHPMA with three of PLGA and three of pHPMA, one 
stent was elaborated with a 20% drug load and the other one with a 50%. This second ratio (50%) 
was chosen as it was one of the most common seen in DES nowadays in the market. Results were 
plotted as seen in Figure 8, concluding that a higher hydrophobic drug load showed a reduction in 
the pharmacological elution over time.  Having studied both factors, drug load and polymeric 
thickness with pHPMA and PLGA, and understanding how they affected their pharmacological 
liberation, new DES could be designed with controlled and tailored release profiles. 
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Figure 8: Sirolimus release of 20% and 50% charged pHPMA and PLGA stents in accelerated medium. Total release was 
plotted as % released from the strut vs time (min). A first stent design was produced by spraying eighteen layers of pHPMA, 
followed by three layers of PLGA and finished with another three layers of pHPMA. All these layers were sprayed with a 
20% sirolimus load. A second stent design was produced the same way as the first stent but with a 50% sirolimus load. As 
concluded from this graph, higher hydrophobic drug load resulted in a reduction in the pharmacological elution over time. 
 
After analyzing data obtain from these experiments, the importance of polymer thickness and 
drug load had been noticed. Next, five new designed stents were prepared. These were made like 
“stent 2” from Figure 8 but with two major changes. First, these stents were produced with a varying 
number of initial layers of pHPMA instead of the original eighteen. Second, only the first pHPMA 
coating contained a pharmacological load while the two other coatings had no drug load. PLGA was 
used to retain and elute in a gentle way the pHPMA loaded base lying underneath, as seen before, 
and the pHPMA as an exterior coating barrier with good adhesion. In order to quantify the amount of 
polymer and drug deposited on different stents, drug loads were expressed in mg of sirolimus/mm2 
of strut. All stents were loaded with a 50/50 drug/polymer ratio).   
Results obtained after analyzing each release were plotted as shown in Figure 9. A release 
reduction was observed while the amount of coating sprayed on the strut was increased using PLGA 
and pHPMA barriers. Data plotted in graph A showed how stent labelled as “1” had slightly more drug 
load than stent “3”, while stent “2” had almost as twice as the other two. This graph represents the 
addition of the release obtained at the different time points plus the final quantity extracted from the 
stent at the end of the experiment. Following, graph B shows how, after one hour, the quickest eluting 
stent was number “3” due to the lack of barrier layers. Stent “1” eluted slower than stent “3” as it 
contained exterior layers acting as barriers, followed by stent “2” being the slowest elution. This 
second stent eluted proportionally lower than stent “1” due to its higher drug concentration. Twenty-
four hours after the first time point (graph C), the differences were not so drastic as in the previous 
graph (B). Stent “3” still showed the fasted elution, followed by numbers “1” and “2” with a smaller 
difference than before (graph B). This was related to the degradation of the barriers over time which 
allowed the drug to escape to the medium reducing their effect gradually.  
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Through this figure a clear relation was established between lower drug elutions due to higher 
sirolimus loads and polymeric barriers with no drug load. These results broaden the knowledge 
obtained to tailor desired drug releases in stents using pHPMA and PLGA. 
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Figure 9: Sirolimus release of different pHPMA and PLGA layered stents with a 50% drug charge. Total release was plotted 
as % released from the strut vs time (h). Graph A: Total liberation obtained from each type of stent, including drug released 
in the medium plus pharmacological load remaining on the strut. Graph B: Release obtained after one hour from each type 
of stent. Graph C: Release after twenty-four hours from each type of stent. On graphs A-C the columns from left to right 
represent the following stent composition. Starting with the strut’s interior layer to its most exterior layer: PHPMA 
(sirolimus, 0.81 mg/mm2), three layers of PLGA and three layers of pHPMA (stent 1). PHPMA (sirolimus, 1.36mg /mm2), 
three layers of PLGA and three layers of pHPMA (stent 2). PHPMA (sirolimus, 0.73 mg /mm2) (stent 3). Slower elutions 
were observed on stent designs which contained polymer barriers (stents 1 and 2), being the stent with more drug 
concentration (stent 2) the one to exhibit a slower release.                                 
 
 
These results showed how barriers and drug concentration could affect drug elution, but in order 
to have more detailed information on how to effectively apply these concepts to PLGA and pHPMA 
multilayers further research had to be done. How would pHPMA barriers differ from PLGA barriers 
and how would a different drug affect pharmacological release? Seeking an answer to this question, 
a varied range of stents was prepared and analyzed as shown next. 
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3.3.3 Elution study of tailored DES with barriers, bursts and different 
drug/polymer combinations in quick release medium.  
On Figure 2, stent composition for following experimentations is detailed. Half of the stents 
were created with an interior layer of pHPMA loaded with sirolimus or PAP-1, while the other half 
were composed of PLGA loaded with sirolimus. These stents were either designed with thick or light 
barriers composed of PLGA or pHPMA, or with no barriers at all.  
Figure 10 shows the total release obtained from all these stents plotted on a same graph to 
present an overall image of their behavior.  
Table 2: Composition of different stents for the study of barrier, burst and drug concentration effects. Starting from left to 
right, the first column shows an identification label for each type of stent starting with “S” and followed by a number. In 
the case a label contains a “/”, this indicates the alternative label given to that stent if the drug is changed from sirolimus 
to PAP-1. The second column shows the composition of the interior coating located next to the metallic strut. Some stent 
designs show the possibility of having sirolimus or PAP-1 in their composition, to clarify this, their label will change in the 
previous column depending on the drug they carry (’ or ’’ indicates a PAP-1 load). The third column shows the composition 
of the exterior layers coated on top of the interior layers shown at the previous column. In the composition description of 
this third column some layers may be described with more than one polymer, from left to right (S3’’) being the one in the 
left the most interior layer and the one at the right the most exterior layer. The last column shows the drug load of each 
stent in μg/mm2. This table was designed as a quick composition reference for the next experiments. 
Stent 
Composition and nº 
 of Interior layers 
Composition and nº 
of exterior layers 
μg/mm2 
S1/S1’  10 pHPMA (Sirolimus/PAP-1)  10 pHPMA 
0.53±0.097 S2 10 pHPMA (Sirolimus) - 
S3/S3’  10 pHPMA (Sirolimus /PAP-1)  10 PLGA 
S3’’ 10 pHPMA (PAP-1) 3 PLGA + 3 pHPMA 0.52±0.092 
S4 10 pHPMA (Sirolimus) 10 PLGA (Sirolimus) 0.68 
S5 10 PLGA (Sirolimus) - 
0.45±0.103 S6 10 PLGA (Sirolimus) 10 PLGA 
S7 10 PLGA (Sirolimus) 10 pHPMA 
S8 10 PLGA (Sirolimus) 10 pHPMA (Sirolimus) 0.92 
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Figure 10: Sirolimus release from a wide variety of stents composed of pHPMA and PLGA coatings for the study of burst 
and barrier effects with sirolimus and PAP-1. Total release was plotted as % released from the strut vs time (h). Composition 
of all stents is described in Table 1. Results obtained through thorough analysis of this data led to the verification of barrier 
and burst effects with different combinations of PLGA and pHPMA coatings.  
Figure 10 is broken down into 10 separate graphs which make the discussion of the phenomena 
observed easier and enables a fluid discussion of the results. With the intention of comparing the 
effects of PLGA and pHPMA barriers, two different graphs were elaborated (Figure 11) using data 
from Figure 10. Both graphs are followed by a small sketch located under them, which clarifies the 
layer composition of each stent. 
t im e  /  h
R
e
le
a
s
e
 %
0 1 0 2 0 3 0 4 0 5 0
0
2 0
4 0
6 0
8 0
1 0 0
S 1
S 2
t im e  /  h
R
e
le
a
s
e
 %
0 1 0 2 0 3 0 4 0 5 0
0
2 0
4 0
6 0
8 0
1 0 0
S 5
S 6
Figure 11: Comparative release study with PLGA and pHPMA barriers in stents of polymeric homogenous composition. 
The top left graph shows elution from stents composed of pHPMA layers loaded with sirolimus (S1 and S2) with pHPMA 
barriers (S1) followed by a layer diagram located under it. The top right graph shows elution from stents composed of 
PLGA layers loaded with sirolimus (S5 and S6) with PLGA barriers (S6) also followed by a layer diagram. Results showed 
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how PLGA improved barrier effectiveness over PLGA matrices when compared with pHPMA barriers over pHPMA 
matrices. 
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On the left graph on Figure 11 two releases are compared. S1 showed a lower initial liberation 
than S2, as the first one contained a pHPMA exterior barrier which hold back the sirolimus elution. 
As the pHPMA barriers degraded, sirolimus started to leak into the media crossing through small 
pores and diffusing through its polymeric matrix. On the right graph, a similar experiment was 
performed. These stents were similar to S1 and S2, but in this case, coatings were elaborated with 
PLGA instead of pHPMA. S6 showed a high sirolimus retention, as it had an exterior barrier of PLGA 
which S5 did not have. PLGA degraded slower than pHPMA, this behavior was clearly seen on the 
elution profile. When comparing both graphs, PLGA barriers acted in a more aggressive manner than 
pHPMA barriers, which were subtler. This phenomenon was interesting as it can be used to elaborate 
small reductions on the release profiles, as well as it may be used to create a thin exterior layer which 
can be used to enhance adhesion between the polymeric matrix and the artery wall without practically 
affecting the overall release. 
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Figure 12: Comparative release study with PLGA and pHPMA barriers in stents of polymeric homogenous and 
heterogeneous composition. Top left graph shows elution from stents composed of pHPMA layers loaded with sirolimus 
(S1, S2 and S3) and in some cases coated with pHPMA (S1) or PLGA (S3) barriers, followed by a layer diagram located 
under it. Top right graph shows elution from stents composed of PLGA layers loaded with sirolimus (S5, S6 and S7) and in 
some cases coated with PLGA (S6) or pHPMA (S7) barriers, also followed by a layer diagram. Results show different 
behaviors obtained from pHPMA and PLGA barriers over PLGA or pHPMA matrices. 
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On Figure 12, an extra release profile from Figure 11 was added to both graphs with the aim of 
studying the barrier effects seen before while combining different polymeric matrices. On the left 
graph, a release profile was added belonging to a stent with the same interior sirolimus loaded 
pHPMA coating but with a PLGA exterior barrier. Although on normal circumstances pHPMA eluted 
very quickly, this PLGA exterior barrier showed a controlled and slower release which did not result 
in an aggressive pealing or detachment of the interior layers. The behavior described is crucial, as if 
this was not the case, the combination of polymers described would not be suitable for the elaboration 
of multi-layered stents. On the right graph, a release profile was added belonging to a stent with an 
interior sirolimus loaded PLGA coating, but with a pHPMA external barrier. As expected, the release 
profile of this stent laid in between of the ones obtained from S5 and S7. Its barrier was presumed to 
reduce elution under S5’s profile, but not lower than the curve obtained from S6. Both combinations 
seen on Figure 12 showed a controlled release with a good behavior and no signs of peeling. There 
was one more effect which was of interest in this set of experiments and which is presented in Figure 
13. 
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Figure 13: Release profiles used to study drug ratio and hydrophobicity effect on designed stents. These graph, 
based on the ones depicted in Figure 12, show the addition of S4 (on the left) and S8 (on the right) in order to study 
how their composition varied their release profile. Each graph is followed by a diagram which describes the 
composition of the stents used. Results show how drug concentration effects can have a greater impact on drug 
release profiled than barriers. 
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This graph shows the change in elution obtained when the barrier layers were filled with a 
pharmacological load. Through this experimentation the new coatings performed differently, 
producing interesting results. These new profiles were added to the ones shown in Figure 12 to make 
the discussion easier to follow, leading to Figure 13. On the left graph, a release profile was added 
belonging to a stent with an interior sirolimus loaded pHPMA coating, with a sirolimus loaded PLGA 
external layer. When the new profile was graphed, its initial release showed a slower elution when 
compared to S1 and S2, but quicker than S3. In the case of S4, its external PLGA layer was loaded 
with sirolimus. This led to an initial liberation higher than the one observed with S3, but as the coating 
started to fade and erode, the release from the PLGA matrix produced once again a slower elution 
than the one obtained from the pHPMA matrix of S3.  
Most important, this showed that the influence of pharmacological load described previously, 
where a higher drug load rendered a reduction in the release profile, was having a greater impact in 
these stent elution profiles than the barriers. On the right graph, this phenomenon was very clear as 
the drug load present on stent S8 was twice than the rest.  After analyzing these results, effective 
barriers could now be designed with PLGA and other reductive effects could be achieved at the 
expense an increase in the pharmacological load. 
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Figure 14: Effect of PLGA and pHPMA barriers over PAP-1 or sirolimus loaded matrices. Each graph is followed by 
a layer diagram placed under it. The graph at the left shows elution from a bilayered stents with an interior pHPMA 
coating loaded with sirolimus (S3) or PAP-1 (S3’) and an exterior barrier of PLGA (S3 and S3’). At the right, a graph 
shows elution from a bilayered stents with an interior pHPMA coating loaded with sirolimus (S1) or PAP-1 (S1’) and 
an exterior barrier of pHPMA (S1 and S1’). Elution profiles show differences due to hydrophobicity of the drug loaded 
in the polymeric matrices as well as the type of barriers used.  
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After observing the effect of sirolimus concentration on the release profile, Figure 14 shows the 
addition of two new profiles which come from the substitution of sirolimus by a more hydrophobic drug 
(PAP-1) in S1 and S3 stents. On the left graph, substituting sirolimus by PAP-1 in the interior layer 
and adding a strong PLGA barrier caused the release to drop drastically. On the other hand, in the 
graph located at the left, substitution of sirolimus with PAP-1 rendered a slower elution due to its 
increased hydrophobicity. It was also noticed that the pHPMA barrier causes a very subtle blocking 
effect with this drug. Once results from these experiments had been studied, the next step led to the 
tailoring of PAP-1 elutions in different stent configurations. Releases obtained from some initial 
designs are shown in Figure 15. 
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Figure 15: Tailoring PAP-1 elution through the study of various releases form 
different stent formulations. This graph is followed by a layer diagram placed 
under it Three different stent designs were studied with the objective of 
obtaining a suitable release which could last over 1 month for a future in-vivo 
model. Different burst, barrier and sustained release behaviors were observed.
Stent designs studied in Figure 15 showed tailored compositions and elutions which were 
elaborated to produce results which could be applied in an in-vivo trial. These stents were designed 
with a small exterior layer of pHPMA to enhance arterial adhesion. S1’ displayed a rapid elution 
achieved from the ten interior layers of pHPMA loaded with PAP-1 slightly contained by the next ten 
layers of pHPMA. This profile showed an excessive burst effect lasting up to fifty hours, which would 
not be suitable for a 1 month in-vivo. S3’ was designed substituting the 10 pHPMA layers of S1’ with 
ten layers of PLGA.  
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This long-lasting profile was able to supply sustained elution over 1 month. S3 was elaborated 
by substituting the ten layers of PLGA from S3’ with three layers of PLGA in order to produce a smaller 
barrier. This stent showed a burst effect ranging from twenty-five to seventy-five hours, with a 
continued long-lasting sustained release. Among these three types of stents, S3’’ showed the most 
interesting results for in-vivo testing.  
All these modifications showed that it was possible to tailor the PAP-1 release profile in a multi-
layered stent elaborated with different combinations of PLGA and pHPMA in order to achieve bursts, 
barriers and sustained releases with a good control throughout all its profile.  With the aim of checking 
the morphological structure of the most suited stent for in-vivo testing, SEM images were obtained as 
shown in Figure 16. These images showed a correct abluminal coating for the S3’’ stent. This target 
stent design is studied in detail along the next section. 
 
 
Figure 16: Morphology of S3’’ stent obtained by SEM imaging. S3’’ was composed of ten 
layers of pHPMA loaded with PAP-1, three layers of PLGA and three exterior layers of 
pHPMA. This image shows the abluminal coating at the front in focus, while the luminal 
side remains at the back. A correct abluminal coating is achieved from this multilayered 
stent design.  
 
 
3.3.4 In-vitro testing through scratch test for PAP-1 release in target DES in 
supplemented medium. 
Up to this point, all liberations were performed in modified quick medium to slightly increase the 
stability of the drug and to accelerate the elution. Stent designs discussed from now on were tested 
in full supplemented medium to achieve a more realistic elution environment as well as to observe 
elution times which could better match the ones seen in an in-vivo model. Stents with a full coating 
of pHPMA and others with external barriers of PLGA and pHPMA were tested as seen in Figure 17 
to obtain equivalence between elutions in quick medium and supplemented medium.  
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Slight modifications were made in the extraction of the drug to preserve its stability, such as 
evaporation through N2 currents or CO2 freezing of water content during DCM extraction in order to 
avoid room temperature baths.  An approximation of complete elution times was obtained through 
data analysis and extrapolation, showing that the pHPMA stents loaded with PAP-1 would maintain 
their release up to two weeks. In the case of the pHPMA stents loaded with PAP-1 and with PLGA 
and pHPMA barriers, these would maintain elution up to one and a half months. This last stent was 
found interesting to try in in-vitro and in-vivo experiments due to its controlled liberation and its coating 
material design. Following, a guiding in-vitro experiment was carried out. 
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Figure 17: Evaluation of release from different stents in supplemented medium. Elution profiles obtained in 
supplemented medium can be compared with the ones obtained in quick elution medium. Total release was plotted as 
% released from the strut vs time (h). A fast elution was registered from stents designed with twenty-four pHPMA layers 
loaded with PAP-1. A slow elution was observed from stent designs composed of eighteen interior layers of pHPMA 
loaded with PAP-1, three PLGA layers and three exterior pHPMA layers. Slightly slower elutions are observed in 
supplemented medium when compared with results obtained in quick elution medium. 
 
Now that results had led to a viable stent design which had an interesting elution and an 
adequate material selection, an in-vitro test was done to check that the drug load selected would not 
produce anomalous results. The following test was done to evaluate if the amount released would be 
toxic or if it was enough to produce a change in proliferation. To assess this, a scratch test was 
performed as described at the beginning of this chapter, comparing results of a control culture vs one 
treated with the obtained releases from a target stent. Results are shown next in Figure 18 and Table 
3. 
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Figure 18: In-vitro scratch test adding PAP-1 release to cos-7 cell line from stents composed of eighteen interior layers of 
pHPMA loaded with PAP-1, three PLGA layers and three exterior pHPMA layers (S3’’). The top group of brightfield 
images are obtained from the control group. First column corresponds to images taken at the initial point right after 
producing the standardized scratch and the second column to images taken at twenty-eight hours at the same spot. Rows 
correspond to different controls labelled 1-4 descending vertically.  Controls are treated with culture medium without any 
PAP-1. Under the controls, there are three groups of images corresponding to triplicates of S3’’. In this case, each row 
corresponds to different culture medium used in the experiment. First row (1h) corresponds to samples which were treated 
with culture medium containing release from the first hour of an S3’’ stent. Second row corresponds to samples treated 
with culture medium containing the release obtained starting from the first hour up to twenty-four hours. This tendency 
continues descending vertically until the last row, which contains the release obtained during the period between ninety-
six to one hundred and sixty-eight hours from a S3’’ stent. This experiment was performed in triplicate, labelling each 
iteration as A1, A2 and A3. No toxicity is observed as well as a reduction in proliferation. 
A1 A2 A3 
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Table 3: Wound healing evaluation from in-vitro scratch test performed to cos-7 cultures exposed to liberations 
obtained from stents composed of eighteen interior layers of pHPMA loaded with PAP-1, three PLGA layers 
and three exterior pHPMA layers. Results obtained from Figure 18 expressed in % area of closed wound. The 
top table corresponds to the bottom group of images from the previous figure (A1-A3). First column shows the 
time lapse from which the release medium was used. Second to fourth columns show % area of closed wound 
of stents A1-A3. Last column shows the average % area of closed wound from each specific time lapse (A1-
A3). Bottom table shows the results obtained from the top group of images of the same figure (Controls). First 
to fourth columns show % area of closed wound of control stents C1-C4. Last column shows the average % 
area of closed wound from all the controls. 
Release from 
time lapse / h 
A1: Cut closed 
during 28h / % 
A2: Cut closed 
during 28h / % 
A3: Cut closed 
during 28h / % Average S1-S3 / % 
0-1 23.5 40.6 28.2 30.8 
1-24 20.5 38.2 41.4 33.4 
24-48 32.0 49.2 49.2 43.5 
48-72 15.5 48.6 73.5 45.9 
72-96 30.5 58.3 58.4 49.1 
96-168 43.3 32.6 66.5 47.5 
 
 
C1: Cut closed 
during 28h / % 
C2: Cut closed 
during 28h / % 
C3: Cut closed 
during 28h / % 
C4: Cut closed 
during 28h / % Average C1-C4 / % 
75.0 87.1 76.0 82.5 80.2 
 
 
 
These results showed how the control samples had almost completely closed the wound after 
twenty-eight hours, while the samples which contained PAP-1 from the DES had not. This slower 
wound healing rate was associated to the antiproliferative action of the drug. These samples had 
been incubated in supplemented medium containing PAP-1 obtained at different time points during a 
drug release study, showing that the amount of drug released was enough to affect proliferation on 
an in-vitro test. Although in-vivo results may broadly vary from the ones obtained in-vitro, this was a 
useful and quick test used to check if the quantity of drug released could affect cells in direct contact 
with the stent. It also showed its antiproliferative action in live cells without any unexpected adverse 
effects, which was a positive indicator sought before moving on to an in-vivo trial. 
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3.3.5 Analysis of tailored PAP-1 loaded DES in supplemented medium. 
Redesigning to find an optimal release.  
 
 
After obtaining these results, the slowest eluting stent from Figure 17 showed an interesting 
profile which was later tried out in a small in-vivo with 3 pigs. Each pig had three stents deployed, 
each loaded with 75 +- 1.2 µg of PAP-1, to be studied for one month before data was collected. 
Although results obtained showed healing and low restenosis, PAP-1 content in blood stream ceased 
to appear after two weeks. As seen in the results, a thick initial pHPMA layer may not be stable 
enough to hold the whole coating structure laid over it and may partially start peeling off when placed 
in an artery. To avoid this, the stent was redesigned to present a more consistent behavior. The initial 
thick coating which provided the sustained release was elaborated with eighteen layers of PLGA 
loaded with PAP-1. Over this polymer matrix a smaller pHPMA coating was added to provide a burst 
effect, leaving the PLGA matrix under it to sustain the structure. A last thin PLGA layer was added in 
order to protect the pHPMA layer and to act as a barrier.  
More studies were carried out with these layer combinations as seen in Figure 19. Three stents 
with this interior PLGA layers and different exterior coatings were prepared as described previously 
to study their different eluting profiles. The aim of this study was to achieve a similar type of release 
than the previous stent design but with a PLGA interior. These profiles were analyzed as presented 
in this figure, showing a burst effect that lasted seventy-five hours. After this time point, the burst 
phenomenon was not appreciated and the effect of the remaining elution from the pHPMA layers on 
the stent was not identified. Another interesting observation was provided by the thicker initial PLGA 
coatings in supplemented medium. The layer combination selected enabled more efficient burst 
effects, leaving the “reduction of release per increase of concentration” effect, observed previously in 
this chapter, to appear much later. In this case, the burst effect of the eight layers of pHPMA over the 
PLGA matrix in supplemented medium was too big if left unprotected, therefore, making the option 
with the PLGA external barrier more interesting. 
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Figure 19: Release profiles obtained from three different stent combinations with PAP-1 drug loads, left in 
supplemented medium for two hundred and fifty hours. Total release was plotted as % released from the 
strut vs time (h). Elution were observed from stent designs composed of the following layers: A first stent 
was composed of eighteen interior layers of PLGA loaded with PAP-1 and eight pHPMA layers also loaded 
with PAP-1. A second type of stent composed of eighteen interior layers of PLGA loaded with PAP-1. A 
third type of stent composed of eighteen interior layers of PLGA loaded with PAP-1, eight pHPMA layers 
also loaded with PAP-1 and three exterior PLGA layers. Burst effects can be observed at the left of the red 
dotted line. To the right of the red dotted line, the PLGA sustained release behavior is predominant. 
 
 
Discarding the unprotected eight layered pHPMA burst stent, the other two were left for twenty 
days in total as seen in Figure 20. As the burst effect faded off on further time points, the stent with a 
higher drug load ended up crossing the other stent’s release profile. As mentioned earlier, this 
phenomenon had been observed when using thicker initial coatings of PLGA in full supplemented 
medium. This study was performed up to a six-hundred-hour time point.  
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Figure 20: Release profiles obtained from PAP-1 loaded stents in supplemented medium during six hundred 
hours. Total release was plotted as % released from the strut vs time (h). Elution were observed from stent 
designs composed of the following layers: A first stent was composed of eighteen interior layers of PLGA 
loaded with PAP-1, eight pHPMA layers also loaded with PAP-1 and three exterior layers of PLGA. A second 
type of stent composed of eighteen interior layers of PLGA loaded with PAP-1. Burst and sustained release 
are achieved with a combination of PLGA and pHPMA. The phenomenon of elution reduction due to an 
increase in concentration is clearly seen at the four-hundred-hour time point, while the burst effect can be 
observed through the initial one hundred hours.  
 
Data obtained from these experiments suggested that an initial PLGA matrix loaded with PAP-
1 and a small protected burst layer of pHPMA can present a suitable release for in-vivo testing ranging 
one to three months. Although the stent which presented a burst effect could be used for future in-
vivo testing, this quick initial release was preferred to be subtler.  As presented next, one last type of 
stents was prepared with a tailored composition which best suited the release profile and 
characteristics sought, slightly reducing the initial burst effect. 
 
3.3.6 Elution study of a final tailored design for multilayered PAP-1 DES. 
 
As to obtain a secure, long-lasting stent with a controlled burst effect, a final design was 
prepared. This one was composed of eighteen layers of PLGA with PAP-1 adhered to the strut, three 
layers of pHPMA with PAP-1 to produce a small initial burst effect and three final pHPMA layers to 
enhance adhesion with the artery wall. These stents were prepared with an industrial sprayer as 
described in the beginning of this chapter. Each stent was weighted after each polymeric coating was 
finished to ensure that the polymer and drug quantities were correct. After finishing the coatings and 
letting them dry for twenty-four hours, three stents were crimped and expanded to check their release 
profile comparing it to uncrimped and unexpanded stents. Release profiles were finished after one 
month and analyzed after, producing the graph seen in Figure 21. 
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Stents that underwent a crimping and expansion process showed a slight reduction in their 
elution. This was attributed to the action of the crimper which compressed and compacted the stents 
coating as well as possibly removing a very small part of the external pHPMA layers which could stick 
to the crimper during the process. Although this phenomenon is very common, it could affect the 
release profile of the designed stent making the study of the possible elution deviation interesting. In 
this case, the reduction observed was quite small and practically did not change from the uncrimped 
stents. As the figure shows, there was a clear area where the pHPMA burst could be appreciated, 
lasting up to two hundred hours. After that, the effect of the pHPMA could not be considered a burst 
effect and the elution was PLGA matrix predominant.  
Three different regions were defined when examining the changes in the slopes throughout the 
elution time. In Table 4, the different slope ranges are listed for the different stents studied in Figure 
21. Starting from the top, the blue row represents the fastest burst effect of the outer layers of pHPMA 
shown during the first twenty-five hours. After that, a purple area shows a smaller slope corresponding 
to the rest of the burst effect and the interior layers of pHPMA which started to be mixed with the 
PLGA matrix. On the last area colored as red, some pHPMA still remained but only mixed with the 
most exterior layers of PLGA. This small quantity of PAP-1 slightly increased the expected release 
from a PLGA matrix. This residual elution is caused by three different phenomena. First, an interface 
between two layers can contain a mix of both, showing a small content of a drug eluting when its layer 
has already completely eluted. A drug may also diffuse slightly into another layer, showing this 
remaining elution described previously. Something which should also be considered is that 
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Figure 21: Release profiles obtained from crimped and expanded stents as well as from and 
uncrimped multilayered PAP-1 loaded stents in supplemented medium during eight hundred 
hours. Crimped and expanded stents elutions are compared to the ones obtained from others 
elaborated the same way, but which had not undergone these mechanical processes. The curves 
can be divided into three different areas colored in blue, purple and red corresponding to 
different elution speeds observed. This separation was due to the burst effect obtained from the 
PAP-1 in a pHPMA matrix which faded off gradually. 
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degradation will not occur homogeneously thinning all the exterior layer at the same rate, thus 
producing this residual elution effect. 
Table 4: Mean average slope calculated at highlighted zones for elution curves 
depicted in Figure 21. SA corresponds to an uncrimped and unexpanded stent 
model, while the other three stents have been crimped and expanded. The last 
column of the table shows the slope range of each zone.   
 
SA (ideal) SB SC SD Range 
0.206 0.169 0.170 0.121 0.12-0.21 
0.069 0.061 0.058 0.049 0.049-0.069 
0.018 0.020 0.019 0.014 0.014-0.020 
 
 
The morphology of these stents was also studied through SEM imaging, showing a good 
abluminal coating while the luminal protected part was kept clean. An example of the images obtained 
is shown next on Figure 22. 
 
 
Figure 22: Sem image of a tailored DES produced in an industrial sprayer. 
Composition of these stents was the following: Eighteen layers of PLGA 
(loaded with PAP-1), three layers of pHPMA (loaded with PAP-1) and 
three layers of pHPMA. Layers are listed in interior to exterior order. 
Correct abluminal coating was observed while luminal protected area 
remained clean. 
  
 
This final version, tailored and thoroughly studied, is tested in an in-vivo trial. 
. 
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3.3.7 In-vivo study of PAP-1 loaded stents. 
 
As result from the collaboration with Dr. Mercè Roqué and IDIBAPS (Hospital Clínic de 
Barcelona), a porcine in-vivo trial was possible. Data shown next, as well as the methodology 
described for in-vivo trials on porcine models (materials and methods) is part of their work using our 
last stent model and is presented as found in the submitted article titled “Kv1.3 blockade Inhibits 
Proliferation of Vascular Smooth Muscle Cells In Vitro and Intimal Hyperplasia In Vivo”, currently 
undergoing revision in the journal “Revista Española de Cardiología”. The porcine model used in this 
in-vivo trial is described in the materials and methods section of this chapter. Stents used in this trial 
are loaded with 153.1 +- 0.8 µg of PAP-1 and results obtained are shown next on Figure 23 and Table 
5. 
 
Figure 23: Effect of Kv1.3 inhibition with PAP-1 on Porcine Models of Coronary In-Stent Restenosis. 
Superior: Bar graph representing mean ± SEM of percentage of luminal stenosis of control (n=15) and 
PAP-1-eluting coronary stents (n=12). Inferior: Representative photomicrographs of stented coronary 
segments cross-sections at 28-day follow-up. Verhoeff Van Gieson stain. Original magnification: 10x. 
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Table 5: Morphometric Analysis of the Coronary Stented Arteries. Morphometric data of 
stented coronary arteries are summarized in this table. A mild tendency towards a decreased 
intimal proliferation was observed. 
 
 
 
Although a tendency towards a lesser intimal area in the PAP-1 treatment group can be 
observed, no significant differences in the morphometric parameters analyzed have been 
demonstrated. Several facts may be considered to explain these results. In-vivo release conditions 
may have been different than those estimated in vitro, and the drug may not have been properly 
released. Supporting this point of view, we have analyzed the remaining PAP-1 concentration in the 
stented segments, which is approximately 40-50% of the initial concentration, therefore implying the 
release was not complete, as expected by the preliminary experiments of release profile analysis. 
Another possible explanation for the lack of effect is the limitation of PAP-1 concentration which could 
be incorporated into the polymer. In our in vitro assays, a maximum concentration of 1.5 𝜇g/mm2 was 
achieved, preserving an adequate electron microscopy structure of the coated stent. It is possible 
that higher concentrations of the study drug would have produced a more effective reduction in intimal 
proliferation. In summary, implantation of PAP-1-eluting stents did not result in a statistically 
significant decrease of intimal proliferation in the coronary arteries, compared to polymer alone coated 
stents, although a mild tendency towards a decreased intimal proliferation was observed. 
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To note, it is debated whether late vascular response (i.e., neointimal formation after 28 days) 
after DES implantation in swine models may or may not correlate with clinical restenosis or increased 
target legion revascularization (TLR) in clinical trials out to 4 years long-term. In addition, it has been 
suggested that long-term time points in pig models should be used for safety and biocompatibility 
assessment as they remain insufficiently validated for efficacy endpoints. The polymer used in our 
stent has shown to have no side-effects, like excessive inflammation or fibrin deposition. Also, there 
was no evidence of occlusive or residual thrombosis in any of the stented coronary segments 
analyzed. Reendothelialization was also analyzed, which was complete, with 100% of endothelial 
lining recovered at 28 days after stent implantation, in PAP-1 and control treatment groups. 
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3.4 Concluding Remarks 
 
 
Throughout this chapter, the elution of sirolimus and PAP-1 from pHPMA and PLGA matrices 
with multilayered stents has been studied. The knowledge provided by the results of these 
experiments have enabled the creation of burst layers, barriers and different sustained release 
profiles which can be used to modify sirolimus and PAP-1 elution from medical devices. pHPMA 
matrices have shown very quick releases which are useful for burst effects but have shown to be 
unreliable for thick interior layers as they may peel off. PLGA matrices have shown sustained releases 
with PAP-1 and sirolimus which have been studied in different mediums and with different drug loads. 
Stents loaded with these drugs have shown slower elutions with PAP-1 than with sirolimus due to 
difference in hydrophobicity.  
A reduction in the drug release has been observed during the experiments, associated to an 
increase of pharmacological load. This phenomenon has been studied in a variety of cases with 
sirolimus and PAP-1 in different polymeric matrices and has proven to produce a greater effect than 
barriers but at the expense of a greater drug concentration. This behavior has been observed in long 
duration releases in supplemented medium, appearing later than burst effects in exterior layers. The 
combination of these two phenomena can be tailored to appear at a same liberation curve, becoming 
helpful tools used to modulate releases. 
All the knowledge provided by this experimentation has enabled the elaboration of multilayered 
stent designs which can tailor drug liberation to be suited for different applications. These outcomes 
have generated interesting stent designs which have been tested in-vitro and in-vivo with promising 
results. A multilayered stent used for a last in-vivo trial has been elaborated in an industrial 
environment to prove the scalability of the process. The images and release profiles obtained from 
the stents created have shown the viability of its industrial production. Although restenosis reduction 
was achieved when compared with control stents in a porcine model in-vivo trial, future animal testing 
is suggested to achieve multilayered combinations and PAP-1 concentrations which can reduce 
restenosis in a more efficient manner. Furthermore, the polymer used in our stents has shown to have 
no side-effects, like excessive inflammation or fibrin deposition. Also, there was no evidence of 
occlusive or residual thrombosis in any of the stented coronary segments analyzed. 
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4.1 Introduction 
Throughout the previous chapters, CAD treatment has been approached through DES 
tailoring. The main reason for this was DES being the most common solutions for CAD treatment, 
with overall good results [1]–[6]. Another issue addressed was that although there are a variety of 
DES present in the market, none presents an optimal model which solves all the derived 
consequences of stent implantation. Due to the lack of a unique solution, a variety of different 
methods based on drug delivery systems and gene therapy systems have been tested out. Results 
from these drug eluting stents have been obtained by elution analysis of pharmacological release 
and in vitro or in vivo testing [7]–[14].  
A second approach, gene therapy, is a technique that uses nucleic acids to treat or prevent 
diseases by acting on the genetic roots of the illness [15][16]. The goal of gene therapy is to modify 
a gene, or genetic pathway, to prevent or treat a disease. Although gene therapy can be applied with 
DES treatment, it would render better results if eluted with a carrier that ensured a controlled delivery. 
There have been different techniques developed to treat inflammatory responses through gene 
modification, but these efforts have not been directed to achieve restenosis reduction through 
controlled release with DES. One of the most promising carriers used which enables safe and 
efficient delivery systems are nanoparticles [9][17]–[20]. 
When applying nanoparticles locally, they can penetrate the vessel wall and form a depot 
which will allow a sustained release of drugs into the arterial wall. This method allows a focused 
treatment which targets affected cells [21]. Nanocarriers can be tailored to have specific sizes, 
shapes, densities or functionalities. Customization makes nanoparticles ideal as drug delivery 
vehicles when used to encapsulate desired drugs or gene vectors. It is of vital importance to ensure 
the non-toxicity of the nanoparticles used for drug delivery, as they are going to be used to penetrate 
the targeted cells [22]. As mentioned before, nanoparticles can be excellent carriers and can prove 
useful when developing a therapeutic strategy for DES. Achieving a controlled release of 
encapsulated contents is possible as long as adhesion of nanoparticles to a stent surface is 
guaranteed. A good range of biodegradable and biocompatible materials have been tried out to fulfil 
this task, showing there is no unique solution to this question. Up to date, DES have been made of 
different polymers, but some of the most used ones are poly(lactic acid) and poly(lactic-co-glycolic 
acid) [23]–[28]. 
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In this study, a promising approach has been implemented to fulfil therapeutic delivery of DES 
through the adhesion of poly(β-amino ester) (pBAE) nanoparticles to the stent strut. If this system 
brings positive results, on one hand, it will be useful to deliver antiproliferative drugs. On the other 
hand, it will also be useful to ensure controlled and localized release of a large number of microRNA 
(miRNA). These endogenous, noncoding, single-stranded RNAs have been demonstrated to reduce 
proliferation of smooth muscle cells, which is a key factor for stent treatment. miRNAs are novel 
regulatory RNAs for neointimal lesion formation, making them a useful tool for the treatment of 
proliferative vascular diseases such as atherosclerosis, postangioplasty restenosis, transplantation 
arteriopathy, and stroke [29]. Our approach can also enhance the therapeutic treatment, as it 
provides a regulated release of small interfering RNA (siRNA), which have an important role on 
regulating the inflammatory process [30]. This tailored release is able to span over an initial burst, 
producing a better controlled pharmacological liberation. 
pBAEs used in this study have previously shown high transfection efficiencies, biodegradability 
and biocompatibility. Furthermore, nanoparticles made from these polymers can be tailored in a cell-
specific manner by changing their composition [31]. Recently, pBAEs have been used in different 
therapeutic applications and proven successful. Multiple applications have been described in stem 
cell modification or osteodifferentation, showing great promise to deliver interfering RNA (RNAi) in a 
safe way [32][33]. Since different backbone structures can be easily designed for pBAEs, there is a 
great variety of polymers to choose from [34][35].  
In previous studies, results show that polymer structure has a direct influence on RNAi binding 
and delivery efficiency, concluding that the polymer structures C6 and C32 outperformed most of the 
rest [36]. These polymers show a high flexibility and can be easily tuned to fulfil specific 
purposes [33][37]–[39]. Due to this flexibility, different strategies have been tried out in order to 
produce nanoparticles with pBAEs. Positive results have been achieved, demonstrating that they 
can act as functional nanocarriers with a low toxicity [40]. 
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Research in this area has led to an approach which focuses on creating pBAE based 
nanoparticles for drug delivery/gene therapy systems designed to prevent in-stent restenosis. 
Controlled delivery mechanisms using pBAEs are achieved in this study through the chemical 
bonding of nanoparticles to an initial polymer layer adhered to the stent strut. This first layer is 
composed of a tailored pentafluorophenyl methacrylate (PFM) coating which enables the chemical 
adhesion of nanoparticles, avoiding the instantaneous total release of the carriers when in contact 
with the medium. Nanoparticles will bond to the PFM layer; therefore, it is of great importance to 
produce a coating which maintains the highest number of aromatic groups as possible to enhance 
adhesion. While polymerization is carried out on a stent strut, the luminal part remains protected to 
ensure the polymer will only be deposited on the abluminal side. Chemical adhesion of the 
nanoparticles and their usefulness in gene therapy are also tested. 
As discussed, although there have been several advancements in the understanding and 
treatment of atherosclerosis, there is still much more to be done. Our proposal hopes to open a 
pathway for pharmacological and/or gene delivery systems based on the plasma-enhanced adhesion 
of pBAE nanoparticles on PFM layers for stent implantation. Once a PFM layer is adhered to the 
substrate, pBAE nanoparticles will bond to the polymer due to its chemical nature. In this case, the 
carbonyl group from the esters of the PFM chains react with the amine group from the nanoparticles 
through a nucleophilic substitution reaction with pentafluorophenol acting as the leaving group [41]. 
This process is illustrated on Figure 1. 
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Figure 1. Schematic representation of the coating process with pentafluorophenyl methacrylate (PFM) and nanoparticles 
on a stent strut. Image at the top left shows PFM monomer being activated in a plasma reactor. Top right image shows 
PFM bonded to the sample surface after the activation process. Bottom left image shows how nanoparticles bond to the 
PFM and image at the bottom right shows how, after being treated with bovine serum albumin (BSA), the samples are 
seeded with cells. 
 
We believe that through the bonding of carriers to a polymeric layer attached to a stent, a 
controlled and localized treatment can be achieved. This method will ensure the persistence of 
loaded nanoparticles on the stent, avoiding the carriers to be completely removed through the blood 
stream at first contact. When a stent is expanded at the affected area, nanoparticles will stay on the 
polymer matrix and mostly penetrate the target adjacent cells on to which they are pressed. This 
approach can render a higher nanocarrier efficiency due solely to the tailored release method. This 
leads to the main objective of this chapter, described previously in chapter I: 
- Develop a strategy to coat stents with nanocarriers which can show a good adhesion and 
avoid the washing away of the nanoparticles when deployed. 
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4.2 Materials and methods  
Materials 
 
Tween-20 detergent and Bovine Serum Albumin (BSA) were obtained from Sigma-Aldrich (St. 
Louis, United States). Pentafluoro phenyl methacrylate (PFM) was obtained from Manchester 
Organics Ltd. (London, England). Dulbecco’s Modified Eagle Medium was provided by Lonza (Basel, 
Switzerland) and fetal bovine serum by Cultek (Madrid, Spain). Glutamine and penicillin/streptomycin 
were obtained from Labclinics (Barcelona, Spain). Petri dishes and well plates were provided by SPL 
Life Sciences (Naechon-myeon, South Korea) while eppendorfs by Thermofisher (Waltham, United 
States). Trypsine was obtained from Gibco Life Technologies (New York, United States). Chromium 
Cobalt Alloy CrCo stent struts and electropolished CrCo discs (20 × 1 mm) were made from alloy 
L605 and provided by IberHospiTex (Barcelona, Spain). Glass wafers were provided by Labbox 
(Barcelona, Spain). Medical silicon used to develop the silicon wafers was obtained from Nusil 
Technologie Europe (Mougins, France) and COS-7 cells (CRL-1651TM) were provided by ATCC 
(Manassas, United States). 
 
Oligopeptide-ended pBAE were synthetized in-house through a method previously described 
by our research group [31][42]. Briefly, poly(β-amino ester)s were synthesized following a two-step 
procedure. First, an acrylate-terminated polymer was synthesized by addition reaction of primary 
amines with diacrylates (at 1:1.2 molar ratio of amine:diacrylate). Then, pBAEs were obtained by end-
capping modification of the resulting acrylate-terminated polymer with different kind of amine- and 
thiol- bearing moieties. In general, oligopeptide-modified pBAEs were obtained by end-modification 
of acrylate-terminated polymer C32 with thiol-terminated oligopeptide at 1:2.1 molar ratio in dimethyl 
sulfoxide. The mixture was stirred overnight at room temperature and the resulting polymer was 
obtained by precipitation in a mixture of diethyl ether and acetone (1:1). 
 
For this paper, tri-arginine end-modified pBAE polymer, C32-CR3 was chosen to be used as 
the polymer for nanoparticle formation: A solution of C32 (0.15 g, 0.075 mmol) dissolved in dimethyl 
sulfoxide (2 mL) and a solution of Cys-Arg-Arg-Arg-CONH2·4HCl (CR3, 0.11 g, 0.15 mmol) in 
dimethyl sulfoxide (1 mL) were mixed and stirred overnight at room temperature. End-modified 
polymer CR3-C32-CR3 was obtained by precipitation in a mixture of diethyl ether:acetone (1:1). 
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Nanoparticle Synthesis 
 
pBAE nanoparticles loaded with green fluorescent plasmid (GFP) were synthetized using the 
method we have previously described [40][42][43]. Briefly, pBAE stock solutions in dimethyl sulfoxide 
(100 mg/mL) were diluted with acetate buffer (25 mM acetate buffer pH 5.0) at appropriate 
concentrations to obtain the desired Polymer–DNA ratios (w/w). An appropriately diluted pBAE (100 
μL) was added to a solution of green fluorescent protein vector (pGFP) (100 μL at 60 μg/mL in acetate 
buffer 25 mM pH 5.0), mixed with vortex vigorously for a few seconds and incubated at 37 °C for 30 
min. These nanoparticles were finally diluted in ultrapure water to achieve the desired working volume 
containing 1 µg/well of pGFP. 
 
Morphology 
 
Scanning electron microscopy (SEM, Jeol JSM-5310, Tokio, Japan) equipped with a 
microanalysis Oxford Instrument Link-Isis software (Abingdon, England) for data analysis, a 
profilometer (Veeco Instruments, DEKTAK 6M, New York, United States), an atomic force microscopy 
(AFM, Park Systems XE 100 Series, Suwon, South Korea) and an infrared (IR) spectrophotometer 
(Thermo Scientific, iS10, Waltham, United States) with a complementary Attenuated Total Reflection 
(ATR) accessory (Thermo Scientific, Smart ATR, Waltham, United States) were employed to 
characterize shape, thickness, rugosity and quality of the surfaces produced. To obtain SEM images, 
samples required a gold coating which was obtained with a mini sputter Coater (Quorum, SC7620, 
Lewes, UK). AFM was used with a non-contact mode. Samples were placed over a sample carrier 
disc and fixed with double-sided adhesive tape at room temperature in a vibration-free environment. 
 
In Vitro Transfection Assay 
 
COS-7 cells were cultured in Dulbecco’s modified Eagle medium (DMEM) with 10% fetal 
bovine serum (FBS), 1% penicillin/streptomycin and 1% glutamine. These cells were grown in Petri 
dishes up to 90% confluence in their culture medium at 37 °C under 5% CO2. The cells were 
harvested by trypsination, collected by centrifugation (5 min at 130× g), resuspended and counted in 
a Neubauer chamber (Thermofisher, Waltham, United States). 
 
After completing the synthesis of nanoparticles, which encapsulate pGFP, the glass samples 
with PFM were taken out of the reactor and placed in a 24 well plate. All samples were covered with 
a nanocarrier solution and left for two hours to ensure the chemical binding. Later, all wells were 
aspirated and either washed with BSA, or left unwashed. BSA was left for one hour on the selected 
wells before being aspirated. Cells were seeded at a density of 50,000 cells per well in 24 well plates 
for the glass disc samples. CrCo disc samples required seeding 100,000 cells per well in 12 well 
plates. Cells were left incubating in supplemented medium for 24 hours (h) before checking 
transfection for the first time, and later checked again at 48 h. 
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When reproducing this process with metallic stents, small variations had to be done. In this 
case, 6 well plates were seeded with 150,000 cells per well in 3 mL of supplemented medium each 
and left incubating for 2 days. Once accomplished, stents were coated with PFM and left for 2 h in a 
1.5 mL eppendorf with the nanoparticle solution. Later, all eppendorfs were aspirated, washed with 
BSA and left for 1 h in this solution. After completing this process, stents were ready for in vitro testing. 
Following, stents were added to the wells to start the transfection assay. Images were taken 24 and 
48 h after. 
 
Plasma Polymerization Reactor 
 
A plasma deposition apparatus which consists of a stainless-steel discharge vessel (diameter: 
26 cm, length: 24 cm) parallel plate reactor was used throughout the whole experimentation. In this 
model the ground electrode is the reactor chamber itself, and the radiofrequency (RF) electrode is a 
stainless-steel plate. All the samples were treated on the central part of this plate. The RF electrode 
was connected to a RF pulse generator (13.56 MHz) via a matching network. The O2 used to clean 
the reactor was added through a flux controller while the monomer was supplied via a standard 
manifold which was able to adjust gas flux using needle valves.  
 
System pressure was determined by a Pirani type vacuum meter, located between the reactor 
and a cold trap which was fed with dry ice. The two-stage mechanical pump (RV12 903, Edwards, 
GB, Bolton, England) is located after the cold trap, and evacuates the vessel to a reactor chamber at 
pressure of 0.1 mbar. All polymerizations were performed on silicon wafers, glass wafers, CrCo discs 
and CrCo stent struts. These samples were treated under pulsed plasma with a pulsed RF power 
ranging from 12 to 52 W, duty cycles (DC) of 10/20, 2/12, 2/22 and 2/52 with deposition times from 5 
to 65 min. Before starting the polymerization, the monomer (PFM) and the entry lines were preheated 
with heating jackets up to 75 °C. After preheating, monomer (PFM) flow was stabilized and fixed to 
achieve an internal reactor pressure of 0.35 mbar. A diagram of the reactor used can be seen 
in Figure 2. 
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4.3 Results and Discussion   
 
4.3.1  PFM coatings through plasma polymerization 
 
Due to the unique geometry of this reactor and the variety of surfaces which were coated 
(glass, CrCo disks and stents), plasma polymerization conditions had to be optimized. Finding the 
ideal parameters for this reactor was crucial in order to ensure the maximum number of functional 
groups on the PFM coatings. This allowed an increase in the number of nanoparticles attached to the 
surface, thus accomplishing the highest therapeutic activity possible. To ensure the maximization of 
functional groups on PFM layers for each sample, different parameters were tested to optimize the 
process in our reactor, as shown in Table 1. 
 
 
Figure 2. Schematic diagram of stainless steel vertical plasma reactor and its electrical 
components:  
(1) monomer feed, (2) gases feed, (3) cylindrical chamber, (4) holder sample, (5) pirani 
gauge, (6) matching box and electrical system, (7) cold trap, and (8) chemical trap. 
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Table 1. Three different plasma processes are defined with a ton = 2 ms for the exception of the first one 
(ton = 10 ms). As this first process is the one commonly used in our laboratory it was used as a reference 
to compare results. In this experiment tprocess refers to the time it takes to complete a polymerization, 
starting when plasma is generated inside the reactor and finishing when the reactor is turned off. As 
expected in plasma polymerization, 𝑪 =
𝒕𝒐𝒏
𝒕𝒐𝒏 + 𝒕𝒐𝒇𝒇
, ton shows the time the plasma pulse is active and toff 
indicates the time the plasma pulse is shut down. Ppeak is the input power given to the system and Peq is 
the equivalent power applied taking in account the time that the plasma pulse is active. 
DC tprocess/min Peq/W Ppeak/W 
10/20 5 7.5 15 
2/12 15 1.9 12 
2/22 30 1.9 20 
2/52 65 1.9 52 
 
 
Samples obtained must be reproducible and show a good stability of the PFM deposited on 
their surface. Time of reaction is also taken into account, but as a secondary objective which should 
be minimized. After the polymerization, each sample was stored in argon atmosphere and an infrared 
(IR) spectrum (Thermo Scientific, iS10, Waltham, United States) was obtained in less than 24 h. 
Spectrums studied were used to obtain a ratio between the signal from the ester and the aromatic 
group. This ratio indicates the stability of the PFM, showing a lower value in the samples which 
maintain their aromatic group. Degradation of PFM results in a reduction of aromatic group signaling, 
causing the ratio (Carbonyl group/aromatic group) to increase its value. Figure 3 shows the results 
obtained after applying the procedure to glass and CrCo disks.  
 
On the two graphs, the same tendencies can be observed for both substrates. Plotted results 
were separated in three different groups labelled as A, B and C. Group A shows the highest ratio and 
therefore, the poorest quality PFM obtained. Although the reaction time is very short, quality of the 
PFM coating remains a primary target. Groups B and C obtained a very low ratio (Carbonyl 
group/aromatic group), although group C presented a longer reaction time. Group B shows low ratios 
with low and intermediate reaction times, presenting the best results out of the three groups. Among 
the two DC tested in group B, 2/12 is chosen as the most suitable due to its low ratio and short time 
of reaction. 
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Figure 3. Ratio carbonyl/Aromatic group vs treaction and images of Si samples. Graph labelled (a) 
located at the top left, shows ratio carbonyl/Aromatic group vs treaction for Si samples. At the top right, 
graph (b) shows ratio carbonyl/Aromatic group vs treaction for CrCo samples. These graphs show the 
results obtained through an optimization process elaborated to acquire an optimum coating process. A 
low carbonyl/Aromatic group ratio is desirable as it results in a good quality PFM coating, considering 
a low reaction time as a secondary target. At the bottom of the figure, image labeled (c) shows samples 
with PFM obtained after polymerization. First row of samples displays coated CrCo discs, while second 
row displays coated glass discs. Starting from left to right, the following DCs have been used: 10/20, 
2/12, 2/22 and 2/52. Among all DC and reaction times tested, 2/12 is selected as optimum due to the 
quality of the coatings produced and the low reaction time achieved. 
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4.3.2  Characterization of optimized PFM surfaces on CrCo surfaces 
Once a DC of 2/12 is chosen as the most appropriate, the polymerized PFM surfaces obtained 
on CrCo discs was characterized through SEM imaging, profilometry and AFM. Film growth rate and 
thickness were obtained by coating different CrCo discs at different time intervals. Profilometry was 
used to determine the step on these different samples. A film growth rate of 3.4 nm/min and a final 
thickness of 79.8 ± 4.6 nm were obtained after a 15 min reaction. In order to obtain some more 
information about the morphology of this PFM coating, an AFM was needed. Not only the final 
thickness was relevant, but also its rugosity. This is an important factor to take in account, as an 
irregular surface may influence negatively in the inflammatory process [44]–[46]. Being so, 
maintaining this parameter to a minimum should be sought.  
An AFM analysis was performed on the samples rendering flat, homogeneous surfaces which 
show the characteristic structures of PFM coatings. Roughness average (Ra) obtained is 0.550 nm, 
root mean square roughness (Rq) is 0.644 nm and maximum roughness (Rmax) is 2.093 nm, as 
shown in Figure 4. While Ra is the most common parameter used, Rq presents useful complementary 
information. Rq amplifies occasional high or low readings, while Ra simply averages them. Rmax 
shows the length of the highest peak obtained. Mean roughness depth (Rz) is the arithmetic mean 
value of the single roughness depths of consecutive sampling lengths. Elaboration of this surface 
morphology was achieved as a result of the experimentation with reactor geometry and the use of 
pulsed plasma conditions. This plasma methodology allows a controlled nucleation and film growth 
with a slow deposition rate, enabling the formation of films with such a low roughness. 
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Figure 4. Data collected from AFM analysis on CrCo surfaces. Characteristic worm-like structure 
from PFM are shown at the top left image. Additional analysis data is presented through Histogram 
(bottom left), Line profile (top right), power spectrum (middle right) and line histogram (bottom right) 
graphs. Attached to the bottom part of the figure, a chart summarizes the roughness data obtained. 
Ra and Rz show values much lower than 1 µm. This reduced roughness values are of vital importance 
when producing an implantable surface which must reduce inflammatory response [44]–[46]. 
As shown in Figure 4, surfaces obtained show reduced values for average roughness. These 
results are desirable when producing a stent surface in order to avoid inflammatory response. AFM 
characterization of the PFM layers showed roughness results much lower than 1 µm (Ra = 0.550 nm, 
Rq = 0.644 nm and Rz = 2.023 nm), producing optimum quality and smooth coatings. Once the 
surfaces obtained had been analyzed, the optimized process was ready to be used throughout the 
experimentation. 
As a next step, a method to attach nanoparticles on to the plasma polymerized surfaces was 
necessary. This will be addressed in the next section.  
Line Profile: Red – 64 
nm 
pxl 
  Line Histogram: Red – 64 
Power Spectrum: Red – 64 
nm3 
nm 
n
µm 
nm 
µm 
1/µm 
µm 
Histogram 
Drug liberation based on plasma-enhanced adhesion of biodegradable nanoparticles 
123 
 
4.3.3  Study of nanoparticle bonding on PFM coatings 
This section describes several experiments carried out in order to test nanoparticle bonding to 
PFM surfaces with no associated toxicity. Initial experiments were carried out on glass discs to ensure 
cells could grow easily on a well-known substrate. Glass waffles were coated with PFM, later taken 
out of the reactor, and placed in a 24 well plate. All samples were prepared as described previously 
in the “In Vitro Transfection Assay” section. Nanoparticles were deposited over the PFM layers and 
incubated for 24 and 48 h, aiming to check for cell morphology and transfection. 
 
 
 
Figure 5. Bright field of various images obtained from COS-7 cells growing with PFM and with/without BSA treatment. 
All the pictures were taken under 10× magnification. The white bar indicates 200 µm. Sites chosen for each experiment 
may show slight variations on initial cell count, resulting on visual diffences in cell concentrations at 48 h. No change was 
appreciated in cell growth when the whole sample was inspected. Normal growth rates and typical morphologies for this 
cell line were observed after 24 and 48 h for controls and PFM with BSA samples. Slight shrinkage and blebbing of cells 
were observed in PFM without BSA samples.  
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First, toxicity of the PFM layer was tested in vitro using COS-7 cells (Figure 5). In this figure, 
images displayed in the first row have been obtained from the control group after 24 and 48 h. Cells 
have grown without any possible detrimental factor, showing an expected growth rate with a 
characteristic healthy morphology for this cell line. On the other hand, the second row shows cells 
growing directly on the PFM layer with signs of stressed morphologies (including shrinkage, blebbing 
of cells and initiation of apoptosis). 
 
In a previous article from our group, PFM has proven to become cytotoxic six hours after its 
polymerization due to the elution of pentafluoro phenol [41]. Its release must be avoided, as this is a 
serious concern for an implantable device. For that reason, images shown in the third row of Figure 
5 aim to solve this issue. This last row shows samples which have been treated to ensure there is no 
liberation of pentafluoro phenol from the PFM layer. Absence of pentafluoro phenol elution was 
achieved through the treatment of PFM layers with BSA for one hour, followed by a gentle rinse. Once 
this process was completed, the PFM surface was prepared to be exposed to the cells. Normal growth 
rates and typical morphologies for this cell line are observed after 24 and 48 h. Results obtained 
conclude that this treatment allows the elimination of pentafluoro phenyl groups, found in excess on 
the PFM surface, avoiding cytotoxicity. This procedure renders a suitable coating for cells to grow on. 
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Figure 6. Dark field images of C32 NPs with and without PFM on COS-7 cells. Images in the left column are taken 24 h 
after cell seeding. At the right column, images are taken another 24 h later at the same area. Total time elapsed since cell 
seeding for images shown at the second column is 48 h. First row shows images from transfected cells deposited over a 
glass disc coated with PFM and C32 nanoparticles. Samples shown on this first row are coated with PFM and 
nanoparticles followed by a BSA treatment and a final rinse. Once this treatment is finished, cells are seeded over the 
samples. Second row shows transfection of cells seeded on glass discs which had C32 nanoparticles deposited on top for 
an hour and then rinsed with BSA. Controls of C32 nanoparticles with no plasmid, with and without PFM have also been 
performed showing black images due to absence of transfection. Results obtained show how nanoparticles which are not 
bonded to PFM are easilly washed away. First row shows how, after bonding, nanoparticles stay attached to the PFM 
coating and are able to transfect cells 24 and 48 h after. All the pictures were taken under 10× magnification. The white 
bar indicates 150 µm. 
 
 
Once the samples were coated with PFM, glass discs were treated with C32 nanoparticles 
which encapsulated pGFP. Nanoparticle bonding was followed by a post treatment with BSA and a 
final BSA rinse. As depicted in Figure 6, samples treated with PFM, nanoparticles and BSA were able 
to transfect even after undergoing a previous rinse. This is due to the bonding process achieved, 
which enabled the adhesion of the nanocarriers to the surface for future release of the encapsulated 
pGFP. On the second row (no PFM coating applied), practically all the nanoparticles had been 
removed after the washing process and very low transfection was identified after 24 and 48 h since 
cell seeding. This clearly shows that without PFM, nanoparticles don’t adhere to the surface and are 
practically completely washed away. These experiments were repeated on CrCo discs, rendering the 
same results. Results obtained with disc samples led to the repetition of experimentation with 
cardiovascular stents. 
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4.3.4  Elaboration of PFM coated stents with bonded nanoparticles 
 
 To reproduce a common stent model which could allow a selective coating, stents were 
masked to protect their lumen. Figure 7 presents an image of the device designed to place the stents 
in the reactor, while the interior area remains masked. 
 
 
 
Figure 7. Image of the structure used to mount the needles which hold the stents in position inside the reactor. A small 
polytetrafluoroethylene plate (100 × 150 × 3 mm) was machined to obtain 10 small conic adapters which were used to 
place the needles. Holes were drilled into the base to match the ones in the reactor and, that way, avoid interfering with 
the monomer flow. Metallic needles were wrapped with polytetrafluoroethylene tape so stents could later be fitted tightly 
to protect their lumen. 
 
 
CrCo stents were treated with PFM and then incubated with C32 nanoparticles and BSA (as 
described above). Part of these stents were analysed by SEM. PFM treated stents which did not 
undergo an immersion process with nanoparticles were used as controls. SEM pictures of both, CrCo 
discs and stents, are presented in Figure 8. 
 
When CrCo disks samples were prepared, their surface was partially masked with a silicon 
wafer. As shown in Figure 8, when removing the wafer, a clear interface could be observed through 
SEM imaging. Both sides of each interface were studied through EDX analysis. Presence of polymeric 
coating was confirmed through the obtention of a clear carbon signal. This result was not obtained in 
areas which had been masked, as no carbon signal can appear over a clean CrCo surface. As shown 
by the SEM images, stent coatings displayed surface uniformity and smoothness throughout all the 
analysed samples. These results are coherent with the low average roughness of the samples 
obtained previously. 
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Figure 8. Analysis of CrCo surfaces coated with PFM. Images labelled as A (A1–A4) correspond to result obtained from 
a CrCo disc. Label B (B1–B3) corresponds to results obtained from a clean stent while label C (C1–C3) represents results 
acquired from a stent coated with PFM. Images A1, B1 and C1 have been taken under 1.75× magnification. Top left image 
shows CrCo disc with a PFM interface (A1). Image A2 is obtained by SEM, where a clear interface was seen. Two sites 
were selected for EDX analysis (spectrum 1 and spectrum 2). A3 and A4 images are the EDX spectra obtained from each 
site. Top right corner of A3 and A4 show their corresponding label which relates them to image A2, where analysis areas 
are tagged. Image B1 was obtained from a clean stent. Image B2 was obtained by SEM and image B3 is an EDX spectrum 
of this clean stent. C1 was taken from a stent coated with PFM. Image C2 shows an image obtained by SEM from this 
coated stent and image C3 shows its respective EDX analysis. Scale is shown at the bottom of each image (A1, A2, B1, B2, 
C1, and C2). Results show how the polymerization procedure rendered PFM coatings on CrCo discs and stents, which 
have been masked to protect specific areas. 
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4.3.5  In vitro transfection study of PFM coated stents with bonded 
nanoparticles  
 
Following experiments required seeding COS-7 cells in 6 well plates which were left to 
incubate for 2 days. Once completed, cell medium was changed and stents with PFM and 
nanoparticles were placed on each well. This plate was left incubating for 24 h and images were 
taken in both light field and fluorescence mode. 
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Figure 9. Transfection of COS-7 cells with NP coated stents. This figure is separated into two different blocks, showing 
results after 24 and 48 h since cell seeding. At the first block and starting from left to right, the first column shows three 
different light field sites. These three images (A1, B1 and C1) were obtained after leaving COS-7 cells in contact with 
stents, which had been coated with PFM and C32 nanoparticles, for 24 h. The second column (A2, B2 and C2) shows 
respective darkfield images of the first column (A1, B1 and C1). A third column shows three different light field sites. These 
images (D1, E1, and F1) were obtained after leaving COS-7 cells in contact with stents, which had been coated with PFM 
and C32 nanoparticles, for 48 h. Next, a fourth column (D2, E2 and F2) shows the respective darkfield images of the third 
column (D1, E1 and F1). Pictures where the stent strut is not seen have been taken from the surrounding area up to 5 mm 
apart from the stent (first row at each block). Images shown in the second and third row of each block have been taken 
from areas where the stent structure is visible. Negative controls with stents containing nanoparticles without plasmid were 
not visible due to absence of transfection. Green signal shows pGFP transfection. 
Microscope observation was repeated 48 h after and results obtained are shown in Figure 9. 
24 h after cell seeding, some transfected cells had started growing over the stent strut as well as 
other cells which were not in direct contact with the stent surface. These transfected cells were 
identified visually due to their fluorescence. Transfection in surrounding areas is explained through a 
small nanoparticle release from the stents surface.  
48 h 
E2 
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As mentioned previously, nanoparticles were covalently bonded with the PFM chains during 
the preparation of the samples. During this process, even after bonding, nanoparticle aggregation 
may occur. Although rinsing the finished stents should eliminate most of the unreacted nanoparticles, 
their polymeric chains may entangle and adhere to others. When introducing one of these stents in a 
different medium, the liberation of aggregated nanoparticles which did not bond to PFM can transfect 
some adjacent cells (approximately a 10%). This initial release was then followed by transfection of 
adhered nanoparticles on the stent surface. More transfection was seen 48 h after cell seeding, and 
new cells start to grow over the stents. 
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4.4 Concluding Remarks 
PFM has been polymerized with a high functional group retention using pulsed plasma 
deposition with optimum conditions in a maximum reaction time of 15 min. Glass and CrCo surfaces 
have been coated with PFM, which was used to attach pBAE nanoparticles through chemical 
bonding. The procedure described in this article has been applied to coat glass and CrCo discs as 
well as CrCo cardiovascular stents. Results obtained have shown the capability of this coating to 
transfect COS-7 cells successfully in an initial screening. This methodology is an interesting and 
viable way of attaching loaded pBAE nanoparticles to stent struts for controlled release. These 
tailored surfaces can be used to develop pharmacological and/or gene delivery systems based on 
the adhesion of pBAE nanoparticles on PFM layers for stent implantation. 
 
A new DES design has been achieved through the development of an original way to adhere 
nanocarriers to produce a tailored release. A strategy has been developed which enables the coating 
of stents with nanocarriers which can show a good adhesion and avoid the washing away of the 
nanoparticles when deployed. These conclusions show how the last aim proposed in chapter I has 
also been accomplished, leading to the end of this thesis. 
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Conclusions 
Through the elavoration of this thesis, an in-lab procedure has been developed to analyze, 
characterize and elaborate multi-layered stents. These methods have enabled a good understanding 
of the composition and elaboration approaches used to produce the market golden standards. At the 
same time, these have been used to guide the initial designs of the stents elaborated in chapter II. 
After evaluating different techniques which allowed the activation and coating of DES, plasma 
activation and spray coating have proven to give best result in a laboratory environment when 
producing multilayered stents. After initial attempts are performed to achieve good quality coatings 
on metallic stent struts, various combinations of PLA, PLGA and pHPMA are successfully sprayed 
while good morphology can be observed through SEM. 
These achievements have permited the elaboration of a broad design variety for chapter III, 
which is focused on the study of the release profiles obtained through the different polymer and drug 
combinations tested. Elution of sirolimus and PAP-1 have been studied from different polymeric 
matrices, leading to elution tailoring obtained through burst layers, barriers and different sustained 
release profiles which can be applied to medical devices. The use of pHPMA has shown very quick 
releases which are useful for burst effects, while PLGA matrices were used for sustained releases. 
These polymer combinations have been studied in different mediums and with different drug loads to 
study concentration, solubility and hydrophobicity effects on the elution. Increase in drug load has 
shown to cause a reduction on DES release and has proven to have a greater effect than barriers at 
the expense of having to add more drug quantity. This phenomenon has been detected in long 
duration releases in supplemented medium and appears later than burst effects created in outer 
layers, making these two phenomena appear at a same liberation curve and becoming helpful tools 
used to modulate releases. 
Through the elaboration of chapter III, the production of multilayered stents with tailored release 
profiles when loading PLGA and pHPMA matrices with sirolimus or PAP-1 has been made possible. 
These outcomes have generated interesting stent designs which have been tested in vitro and in vivo 
with promising results. A multilayered stent used for a last in vivo trial has been elaborated in an 
industrial environment to try the scalability of the process. The data collected from the resulting stents 
have shown the viability of its industrial production. 
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Experimentation discussed in chapter IV has shown that PFM can be polymerized through 
pulsed plasma over CrCo with a high functional group retention to attach PBAE nanoparticles on its 
surface. This technology has been oriented to produce DES coated with PFM and PBAE NPs and an 
initial screening has been performed with cos-7 cells. Results obtained show an interesting and viable 
way of attaching these loaded PBAE nanoparticles to stent struts for controlled and tailored releases 
and opens a pathway for pharmacological and/or gen delivery systems based on this methodology. 
This thesis has contributed with the optimization of different techniques and the elaboration of 
instrumental which allow the production of a laboratory setup for medical device experimentation. 
Results obtained have proven the viability to produce different multi-layered coating systems with 
tailored release profiles which can be applied on medical instrumentation such as DES. These 
methods have been scaled for industrial use and proven to render good results, opening a pathway 
for a new and complete drug release control for medical devices. 
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